Membrane protein targeting engineered deubiquitinating enzymes and methods of use thereof

JP2023548973A5Inactive Publication Date: 2024-11-12FLUX THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023552149
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-06
Filing Date
2021-11-05
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided herein is a fusion protein comprising an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or variant thereof; and a targeting domain comprising a moiety that specifically binds to a membrane protein. Also provided herein are methods of using the fusion protein to treat diseases, including genetic diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 63 / 110,619, filed November 6, 2020, the entire disclosure of which is incorporated herein by reference.

[0002] The present disclosure relates to fusion proteins comprising an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or variant thereof; and a targeting domain comprising a moiety that specifically binds to a target membrane protein. The disclosure further relates to therapeutic methods using the same. [Background technology]

[0003] A subset of genetic diseases is associated with a decrease in the expression level or stability of functional membrane proteins. For example, haploinsufficiency genetic diseases are caused by the presence of a single copy of a wild-type allele heterozygously combined with a loss-of-function variant allele, and the level of expressed functional protein is insufficient to produce the normal phenotype. Haploinsufficiency can result from de novo or inherited loss-of-function mutations in the variant allele, resulting in little or no functional protein being produced. Despite recent advances in gene therapy, there is still no cure for these diseases, and treatment typically focuses on symptom management. Therefore, new treatments are needed for diseases associated with a decrease in the expression or stability of functional membrane proteins, such as genetic diseases. Summary of the Invention

[0004] In particular, the present invention provides an engineered deubiquitinase (enDub) comprising a targeting moiety that specifically binds to a membrane target protein and a catalytic domain of the deubiquitinase. The targeting moiety directs the catalytic domain of the deubiquitinase to the specific target membrane protein for deubiquitination. The fusion proteins described herein are particularly useful in methods for treating genetic diseases, particularly genetic diseases associated with or caused by reduced expression or stability of specific membrane proteins.

[0005] In one aspect, provided herein is a fusion protein comprising: an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof; and a targeting domain comprising a targeting moiety that specifically binds to a membrane protein that is not an ion channel.

[0006] In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease or a metalloprotease.

[0007] In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease, hi some embodiments, the cysteine ​​protease is a ubiquitin-specific protease (USP), a ubiquitin C-terminal hydrolase (UCH), a Machado-Josephine domain protease (MJD), an ovarian tumor protease (OTU), a MINDY protease, or a ZUFSP protease.

[0008] In some embodiments, the cysteine ​​protease is a USP, which may be USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP 19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, or USP46.

[0009] In some embodiments, the cysteine ​​protease is UCH. In some embodiments, the UCH is BAP1, UCHL1, UCHL3, or UCHL5.

[0010] In some embodiments, the cysteine ​​protease is MJD. In some embodiments, the MJD is ATXN3 or ATXN3L.

[0011] In some embodiments, the cysteine ​​protease is an OTU. In some embodiments, the OTU is OTUB1 or OTUB2.

[0012] In some embodiments, the cysteine ​​protease is MINDY. In some embodiments, MINDY is MINDY1, MINDY2, MINDY3, or MINDY4.

[0013] In some embodiments, the cysteine ​​protease is ZUFSP. In some embodiments, the ZUFSP is ZUP1.

[0014] In some embodiments, the deubiquitinating enzyme is a metalloprotease. In some embodiments, the metalloprotease is a Jab1 / Mov34 / Mpr1 Pad1 N-terminal+(MPN+) (JAMM) domain protease.

[0015] In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 1-112.

[0016] In some embodiments, the catalytic domain comprises a catalytic domain derived from a deubiquitinating enzyme that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 1-112.

[0017] In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 113-220 or 293.

[0018] In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:293.

[0019] In some embodiments, the moiety that specifically binds to a membrane protein comprises an antibody, or a functional fragment or functional variant thereof. In some embodiments, the antibody, or functional fragment or functional variant thereof comprises a full-length antibody, a single-chain variable fragment (scFv), scFv2, scFv-Fc, Fab, Fab', F(ab')2, F(v), VHH, or (VHH)2. In some embodiments, the antibody, or functional fragment or functional variant thereof comprises a VHH or (VHH)2.

[0020] In some embodiments, the membrane protein is selected from the group consisting of solute carrier family 2, facilitative glucose transporter member 1 (SLC2A1), proline-rich transmembrane protein 2 (PRRT2), usherin (USH2A), protocadherin-19 (PCDH19), tuberin (TSC2), hamartin (TSC1), dystrophin (DMD), rhodopsin (RHO), Jagged 1 protein (JAG1), inositol 1,4,5-trisphosphate receptor type 1 (ITPR1), sugar transporter SWEET1 (SLC50A1), transmembrane protein 258 (TMEM258), or follicle-stimulating hormone receptor (FSHR).

[0021] In some embodiments, the membrane protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 221-227 or 243-245.

[0022] In some embodiments, the effector domain is operably connected directly to the targeting domain. In some embodiments, the effector domain is operably connected indirectly to the targeting domain. In some embodiments, the effector domain is operably connected indirectly to the targeting domain via a peptide linker. In some embodiments, the effector domain is operably connected indirectly to the targeting domain via a peptide linker of sufficient length to allow the effector domain and the targeting domain to simultaneously bind to their respective target proteins. In some embodiments, the peptide linker comprises the amino acid sequence of any one of SEQ ID NOs: 297-424, or the amino acid sequence of any one of SEQ ID NOs: 297-424 containing one, two, or three amino acid modifications. In some embodiments, the peptide linker comprises the amino acid sequence of any one of SEQ ID NOs: 297-306, or the amino acid sequence of any one of SEQ ID NOs: 297-306 containing one, two, or three amino acid modifications.

[0023] In some embodiments, the effector domain is operably linked, either directly or indirectly, to the C-terminus of the targeting domain. In some embodiments, the effector moiety is operably linked, either directly or indirectly, to the N-terminus of the targeting domain.

[0024] In one embodiment, an effector domain comprising a catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof; an ionotropic glutamate receptor NMDA 2B (GRIN2B), cystic fibrosis transmembrane conductance regulator (CFTR), sodium channel protein type 1 subunit alpha (SCN1A), copper-transporting ATPase 2 (ATP7B), potassium voltage-gated channel subfamily KQT member 2 (KCNQ2), sodium channel protein type 2 subunit alpha (SCN2A), voltage-gated P / Q-type calcium channel subunit alpha-1A (CACNA1A), sodium channel protein type 8 subunit alpha (SCN8A), ionotropic glutamate receptor NMDA Provided herein are fusion proteins comprising a targeting domain comprising a targeting moiety that specifically binds to a membrane protein selected from the group consisting of 2A (GRIN2A), sodium- and chloride-dependent GABA transporter 1 (SLC6A1), sodium / potassium transporting ATPase subunit alpha-2 (ATP1A2), sodium / potassium transporting ATPase subunit alpha-3 (ATP1A3), sodium channel protein type 9 subunit alpha (SCN9A), gamma-aminobutyric acid receptor subunit beta-3 (GABRB3), and potassium voltage-gated channel subfamily KQT member 3 (KCNQ3).

[0025] In some embodiments, the moiety that specifically binds to a membrane protein comprises an antibody, or a functional fragment or functional variant thereof. In some embodiments, the antibody, or functional fragment or functional variant thereof comprises a full-length antibody, a single-chain variable fragment (scFv), scFv2, scFv-Fc, Fab, Fab', F(ab')2, F(v), VHH, or (VHH)2. In some embodiments, the antibody, or functional fragment or functional variant thereof comprises a VHH or (VHH)2.

[0026] In some embodiments, the membrane protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 228-245.

[0027] In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease or a metalloprotease. In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease.

[0028] In some embodiments, the cysteine ​​protease is a ubiquitin-specific protease (USP), a ubiquitin C-terminal hydrolase (UCH), a Machado-Josephine domain protease (MJD), an ovarian tumor protease (OTU), a MINDY protease, or a ZUFSP protease.

[0029] In some embodiments, the cysteine ​​protease is a USP, which may be USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP 19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, or USP46.

[0030] In some embodiments, the cysteine ​​protease is UCH. In some embodiments, the UCH is BAP1, UCHL1, UCHL3, or UCHL5.

[0031] In some embodiments, the cysteine ​​protease is MJD. In some embodiments, the MJD is ATXN3 or ATXN3L.

[0032] In some embodiments, the cysteine ​​protease is an OTU. In some embodiments, the OTU is OTUB1 or OTUB2.

[0033] In some embodiments, the cysteine ​​protease is MINDY. In some embodiments, MINDY is MINDY1, MINDY2, MINDY3, or MINDY4.

[0034] In some embodiments, the cysteine ​​protease is ZUFSP. In some embodiments, the ZUFSP is ZUP1.

[0035] In some embodiments, the deubiquitinating enzyme is a metalloprotease. In some embodiments, the metalloprotease is a Jab1 / Mov34 / Mpr1 Pad1 N-terminal+(MPN+) (JAMM) domain protease.

[0036] In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 1-112.

[0037] In some embodiments, the catalytic domain comprises a catalytic domain derived from a deubiquitinating enzyme that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 1-112.

[0038] In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 113-220 or 293.

[0039] In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:293.

[0040] In some embodiments, the effector domain is operably connected directly to the targeting domain. In some embodiments, the effector domain is operably connected indirectly to the targeting domain. In some embodiments, the effector domain is operably connected indirectly to the targeting domain via a peptide linker. In some embodiments, the effector domain is operably connected indirectly to the targeting domain via a peptide linker of sufficient length to allow the effector domain and the targeting domain to simultaneously bind to their respective target proteins. In some embodiments, the peptide linker comprises the amino acid sequence of any one of SEQ ID NOs: 297-424, or the amino acid sequence of any one of SEQ ID NOs: 297-424 containing one, two, or three amino acid modifications. In some embodiments, the peptide linker comprises the amino acid sequence of any one of SEQ ID NOs: 297-306, or the amino acid sequence of any one of SEQ ID NOs: 297-306 containing one, two, or three amino acid modifications.

[0041] In some embodiments, the effector domain is operably linked, either directly or indirectly, to the C-terminus of the targeting domain. In some embodiments, the effector moiety is operably linked, either directly or indirectly, to the N-terminus of the targeting domain.

[0042] In one aspect, the present invention provides a nucleic acid molecule encoding the fusion protein described herein.In some embodiments, the nucleic acid molecule is a DNA molecule.In some embodiments, the nucleic acid molecule is an RNA molecule.

[0043] In one aspect, provided herein is a vector comprising a nucleic acid molecule described herein (e.g., a nucleic acid molecule encoding a fusion protein described herein). In some embodiments, the vector is a plasmid or a viral vector.

[0044] In one aspect, provided herein is a viral particle comprising a nucleic acid molecule described herein (e.g., a nucleic acid molecule encoding a fusion protein described herein).

[0045] In one aspect, provided herein is an in vitro cell or cell population comprising a fusion protein described herein, a nucleic acid molecule described herein, or a vector described herein.

[0046] In one aspect, provided herein is a pharmaceutical composition comprising a fusion protein described herein, a nucleic acid described herein, a vector described herein, or a viral particle described herein, and an excipient.

[0047] In one aspect, provided herein is a method of producing a fusion protein described herein, comprising introducing into a cell or cell population in vitro a nucleic acid molecule described herein, a vector described herein, or a viral particle described herein; culturing the cell or cell population in a culture medium under conditions suitable for expression of the fusion protein; isolating the fusion protein from the culture medium, and optionally purifying the fusion protein.

[0048] In one aspect, provided herein is a method of treating or preventing a disease in a subject, comprising administering to a subject in need thereof a fusion protein described herein, a nucleic acid molecule described herein, a vector described herein, a viral particle described herein, or a pharmaceutical composition described herein. In some embodiments, the subject is a human.

[0049] In some embodiments, the disease is associated with decreased expression of a functional version of a mitochondrial protein compared to unaffected controls. In some embodiments, the disease is associated with decreased stability of a functional version of a mitochondrial protein compared to unaffected controls. In some embodiments, the disease is associated with increased ubiquitination of nuclear proteins compared to unaffected controls. In some embodiments, the disease is associated with increased ubiquitination and degradation of mitochondrial proteins compared to unaffected controls. In some embodiments, the disease is a genetic disease. In some embodiments, the disease is a genetic disease. In some embodiments, the genetic disease is a haploinsufficiency disease.

[0050] In some embodiments, the disease is a GRIN2B-related disorder, an SCN2A-related disorder, an SCN8A-related disorder, an SLC6A1-related disorder, PRRT2 dyskinesia and epilepsy, a GRIN2A-related disorder, a CACNA1A-related disorder, an SCN9A epilepsy, PCDH19 encephalopathy, GLUT1 deficiency syndrome, recurrent paroxysmal exercise-induced dyskinesia 1, Usher syndrome type 2A, early infantile epileptic encephalopathy type 9, tuberous sclerosis complex type 2; tuberous sclerosis complex type 1, a KCNQ2-related disorder (e.g., epileptic encephalopathy), Becker muscular dystrophy, autosomal dominant RP, Alagille syndrome 1, Gillespie syndrome.

[0051] In some embodiments, the disease is early infantile epileptic encephalopathy type 11, early infantile epileptic encephalopathy type 13, early infantile epileptic encephalopathy type 27, cystic fibrosis, Dravet syndrome, Wilson's disease, recurrent paroxysmal ataxia type 2; epilepsy (e.g., focal with speech impairment and with or without mental retardation), myoclonic-astatic epilepsy, alternating hemiplegia of childhood, alternating hemiplegia of childhood type 2, epilepsy type 7, GABRB3-related epilepsy, or a KCNQ2-related disorder (e.g., epileptic encephalopathy).

[0052] In some embodiments, the disease is a GRIN2B-related disorder, an SCN2A-related disorder, an SCN8A-related disorder, an SLC6A1-related disorder, PRRT2 dyskinesia and epilepsy, a GRIN2A-related disorder, a CACNA1A-related disorder, an SCN9A epilepsy, PCDH19 encephalopathy, early infantile epileptic encephalopathy type 9, early infantile epileptic encephalopathy type 11, early infantile epileptic encephalopathy type 13, early infantile epileptic encephalopathy type 27, cystic fibrosis, Dravet syndrome, Wilson's disease, recurrent paroxysmal ataxia 2 GLUT1 deficiency syndrome, recurrent paroxysmal kinesigenic dyskinesia 1, epilepsy (e.g., focal with speech impairment and with or without mental retardation), KCNQ2 encephalopathy, myoclonic-astatic epilepsy, Usher syndrome type 2A, alternating hemiplegia of childhood, alternating hemiplegia of childhood type 2, epilepsy type 7, GABRB3-related epilepsy; tuberous sclerosis type 2; tuberous sclerosis type 1, Becker muscular dystrophy, autosomal dominant RP, Alagille syndrome 1, or Gillespie syndrome.

[0053] In some embodiments, the target membrane protein is GRIN2B and the disease is a GRIN2B-associated disorder (e.g., epileptic encephalopathy); the target membrane protein is GRIN2B and the disease is early infantile epileptic encephalopathy; the target membrane protein is GRIN2B and the disease is early infantile epileptic encephalopathy type 27; the target membrane protein is CFTR and the disease is cystic fibrosis; the target membrane protein is SCN1A and the disease is Dravet syndrome; the target membrane protein is ATP7B and the disease is Wilson's disease; the target membrane protein is CACNA1A and the disease is The target membrane protein is CACNA1A and the disease is recurrent episodic ataxia type 2; the target membrane protein is KCNQ2 and the disease is KCNQ2 encephalopathy; the target membrane protein is KCNQ2 and the disease is epileptic encephalopathy; the target membrane protein is SCN2A and the disease is an SCN2A-related disorder (e.g., epileptic encephalopathy); the target membrane protein is SCN2A and the disease is early infantile epileptic encephalopathy type 11; the target membrane protein is SLC2A1 and the disease is GLUT1 deficiency syndrome; the target membrane protein is SC The target membrane protein is N8A and the disease is an SCN8A-related disorder (e.g., epileptic encephalopathy); the target membrane protein is SCN8A and the disease is epileptic encephalopathy; the target membrane protein is SCN8A and the disease is early infantile epileptic encephalopathy type 13; the target membrane protein is PRRT2 and the disease is PRRPT2 dyskinesia and / or epilepsy; the target membrane protein is PRRT2 and the disease is repetitive paroxysmal kinesigenic dyskinesia type 1; the target membrane protein is GR The target membrane protein is GRIN2A and the disease is a GRIN2A-associated disorder; the target membrane protein is GRIN2A and the disease is epilepsy; the target membrane protein is GRIN2A and the disease is focal epilepsy; the target membrane protein is GRIN2A and the disease is focal epilepsy with speech impairment and with or without mental retardation; the target membrane protein is SLC6A1 and the disease is an SLC6A1-associated disorder; the target membrane protein is SLC6A1 and the disease is epilepsy; the target membrane protein is SLC6A1 and the disease is myoclonic-astatic epilepsy;The target membrane protein is USH2A and the disease is Usher syndrome; the target membrane protein is USH2A and the disease is Usher syndrome type 2A; the target membrane protein is ATP1A2 and the disease is alternating hemiplegia of childhood; the target membrane protein is ATP1A2 and the disease is alternating hemiplegia of childhood type 1; the target membrane protein is ATP1A3 and the disease is alternating hemiplegia of childhood; the target membrane protein is ATP1A3 and the disease is alternating hemiplegia of childhood type 2; the target membrane protein is SCN9A and the disease is SCN9A epilepsy; the target membrane protein is SCN9A1 and the disease is SCN9A epilepsy; the target membrane protein is SCN9A1 and the disease is epilepsy; the target membrane protein is SCN9A1 and the disease is epilepsy type 7; the target membrane protein is PCDH19 and the disease is PCDH19 encephalopathy; the target membrane protein is PCDH19 and the disease is early infantile epileptic encephalopathy; the target membrane protein is PCDH19 and the disease is early infantile epileptic encephalopathy type 9; the target membrane protein is G The target membrane protein is GABRB3 and the disease is epilepsy; the target membrane protein is GABRB3 and the disease is GABRB3-associated epilepsy; the target membrane protein is TSC2 and the disease is tuberous sclerosis complex; the target membrane protein is TSC2 and the disease is tuberous sclerosis complex type 2; the target membrane protein is TSC2 and the disease is tuberous sclerosis complex type 1; the target membrane protein is TSC1 and the disease is tuberous sclerosis complex; the target membrane protein is TSC1 and the disease is tuberous sclerosis complex type 1; the target membrane protein is TSC1 , the disease is tuberous sclerosis type 2; the target membrane protein is KCNQ3 and the disease is KCNQ2-related disorder (epileptic encephalopathy); the target membrane protein is DMD and the disease is Becker muscular dystrophy; the target membrane protein is RHO and the disease is autosomal dominant RP; the target membrane protein is JAG1 and the disease is Alagille syndrome 1; the target membrane protein is ITPR1 and the disease is Gillespie syndrome; or the target membrane protein is FSHR and the disease is ovarian dysgenesis 1 (ODG1);

[0054] In some embodiments, the fusion protein is administered at a therapeutically effective dose. In some embodiments, the fusion protein is administered systemically or locally. In some embodiments, the fusion protein is administered intravenously, subcutaneously, or intramuscularly.

[0055] In one aspect, provided herein are fusion proteins described herein, polynucleotides described herein, DNA described herein, RNA described herein, vectors described herein, viral particles described herein, and pharmaceutical compositions described herein for use as pharmaceuticals.

[0056] In one aspect, provided herein are fusion proteins described herein, polynucleotides described herein, DNA described herein, RNA described herein, vectors described herein, viral particles described herein, and pharmaceutical compositions described herein for use in treating or suppressing a genetic disorder.

[0057] In one aspect, provided herein is a fusion protein comprising: (a) an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof; and (b) a targeting domain comprising a targeting moiety that specifically binds to a membrane protein that is not an ion channel.

[0058] In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease or a metalloprotease.

[0059] In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease, hi some embodiments, the cysteine ​​protease is a ubiquitin-specific protease (USP), a ubiquitin C-terminal hydrolase (UCH), a Machado-Josephine domain protease (MJD), an ovarian tumor protease (OTU), a MINDY protease, or a ZUFSP protease.

[0060] In some embodiments, the cysteine ​​protease is a USP, which may be USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, USP46, USP47, USP48, USP49, USP49L50, USP49L60, USP49L71, USP49L82, USP49L91, USP49L10, USP49L11, USP49L12, USP49L13, USP49L14, USP49L15, USP49L16, USP49L17, USP49L18, USP49L19, USP40L19, USP41L10, USP41L11, USP41L12, USP41L13, USP41L14, USP41L15, USP41L16, USP41L17, USP41L18, USP41L19 USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, and USP46.

[0061] In some embodiments, the cysteine ​​protease is a UCH. In some embodiments, the UCH is selected from the group consisting of BAP1, UCHL1, UCHL3, and UCHL5.

[0062] In some embodiments, the cysteine ​​protease is MJD. In some embodiments, the MJD is selected from the group consisting of ATXN3 and ATXN3L.

[0063] In some embodiments, the cysteine ​​protease is an OTU. In some embodiments, the OTU is selected from the group consisting of OTUB1 and OTUB2.

[0064] In some embodiments, the cysteine ​​protease is MINDY. In some embodiments, MINDY is selected from the group consisting of MINDY1, MINDY2, MINDY3, and MINDY4.

[0065] In some embodiments, the cysteine ​​protease is ZUFSP. In some embodiments, the ZUFSP is ZUP1.

[0066] In some embodiments, the deubiquitinating enzyme is a metalloprotease. In some embodiments, the metalloprotease is a Jab1 / Mov34 / Mpr1 Pad1 N-terminal+(MPN+) (JAMM) domain protease.

[0067] In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112.

[0068] In some embodiments, the catalytic domain comprises a catalytic domain derived from a deubiquitinating enzyme that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112.

[0069] In some embodiments, the catalytic domain comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 113-220.

[0070] In some embodiments, the moiety that specifically binds to a membrane protein comprises an antibody, or a functional fragment or functional variant thereof. In some embodiments, the antibody, or functional fragment or functional variant thereof comprises a full-length antibody, a single-chain variable fragment (scFv), scFv2, scFv-Fc, Fab, Fab', F(ab')2, F(v), or VHH. In some embodiments, the antibody, or functional fragment or functional variant thereof comprises a VHH.

[0071] In some embodiments, the membrane protein is selected from the group consisting of solute carrier family 2, facilitative glucose transporter member 1 (SLC2A1), proline-rich transmembrane protein 2 (PRRT2), usherin (USH2A), protocadherin-19 (PCDH19), tuberin (TSC2), hamartin (TSC1), and dystrophin (DMD).

[0072] In some embodiments, the membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 221-227 or 243-245.

[0073] In some embodiments, the effector domain is fused directly to the targeting domain.

[0074] In some embodiments, the effector domain is indirectly fused to the targeting domain.

[0075] In some embodiments, the effector domain is indirectly fused to the targeting domain via a peptide linker, hi some embodiments, the effector domain is indirectly fused to the targeting domain via a peptide linker of sufficient length to allow the effector domain and the targeting domain to simultaneously bind to their respective target proteins.

[0076] In some embodiments, the effector domain is fused to the C-terminus of the targeting domain. In some embodiments, the effector moiety is fused to the N-terminus of the targeting domain.

[0077] In one aspect, the present invention relates to a method for producing a ubiquitin-binding protein comprising: (a) an effector domain comprising a catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof; and (b) an effector domain comprising a ubiquitin-binding protein selected from the group consisting of ionotropic glutamate receptor NMDA 2B (GRIN2B), cystic fibrosis transmembrane conductance regulator (CFTR), sodium channel protein type 1 subunit alpha (SCN1A), copper-transporting ATPase 2 (ATP7B), potassium voltage-gated channel subfamily KQT member 2 (KCNQ2), sodium channel protein type 2 subunit alpha (SCN2A), voltage-gated P / Q-type calcium channel subunit alpha-1A (CACNA1A), sodium channel protein type 8 subunit alpha (SCN8A), ionotropic glutamate receptor NMDA Provided herein are fusion proteins comprising a targeting domain comprising a targeting moiety that specifically binds to a membrane protein selected from the group consisting of 2A (GRIN2A), sodium- and chloride-dependent GABA transporter 1 (SLC6A1), sodium / potassium transporting ATPase subunit alpha-2 (ATP1A2), sodium / potassium transporting ATPase subunit alpha-3 (ATP1A3), sodium channel protein type 9 subunit alpha (SCN9A), gamma-aminobutyric acid receptor subunit beta-3 (GABRB3), and potassium voltage-gated channel subfamily KQT member 3 (KCNQ3).

[0078] In some embodiments, the moiety that specifically binds to the membrane protein comprises an antibody, or a functional fragment or functional variant thereof.

[0079] In some embodiments, the antibody, or functional fragment or functional variant thereof, comprises a full-length antibody, a single-chain variable fragment (scFv), scFv2, scFv-Fc, Fab, Fab', F(ab')2, F(v), or VHH. In some embodiments, the antibody, or functional fragment or functional variant thereof, comprises a VHH.

[0080] In some embodiments, the membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 228-245.

[0081] In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease or a metalloprotease.

[0082] In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease, hi some embodiments, the cysteine ​​protease is a ubiquitin-specific protease (USP), a ubiquitin C-terminal hydrolase (UCH), a Machado-Josephine domain protease (MJD), an ovarian tumor protease (OTU), a MINDY protease, or a ZUFSP protease.

[0083] In some embodiments, the cysteine ​​protease is a USP, which may be USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, USP46, USP47, USP48, USP49, USP49L50, USP49L60, USP49L71, USP49L82, USP49L91, USP49L10, USP49L11, USP49L12, USP49L13, USP49L14, USP49L15, USP49L16, USP49L17, USP49L18, USP49L19, USP40L19, USP41L10, USP41L11, USP41L12, USP41L13, USP41L14, USP41L15, USP41L16, USP41L17, USP41L18, USP41L19 USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, and USP46.

[0084] In some embodiments, the cysteine ​​protease is a UCH. In some embodiments, the UCH is selected from the group consisting of BAP1, UCHL1, UCHL3, and UCHL5.

[0085] In some embodiments, the cysteine ​​protease is MJD. In some embodiments, the MJD is selected from the group consisting of ATXN3 and ATXN3L.

[0086] In some embodiments, the cysteine ​​protease is an OTU. In some embodiments, the OTU is selected from the group consisting of OTUB1 and OTUB2.

[0087] In some embodiments, the cysteine ​​protease is MINDY. In some embodiments, MINDY is selected from the group consisting of MINDY1, MINDY2, MINDY3, and MINDY4.

[0088] In some embodiments, the cysteine ​​protease is ZUFSP. In some embodiments, the ZUFSP is ZUP1.

[0089] In some embodiments, the deubiquitinating enzyme is a metalloprotease. In some embodiments, the metalloprotease is a Jab1 / Mov34 / Mpr1 Pad1 N-terminal+(MPN+) (JAMM) domain protease.

[0090] In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112.

[0091] In some embodiments, the catalytic domain comprises a catalytic domain derived from a deubiquitinating enzyme that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112.

[0092] In some embodiments, the catalytic domain comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 113-220.

[0093] In some embodiments, the effector domain is fused directly to the targeting domain.

[0094] In some embodiments, the effector domain is indirectly fused to the targeting domain.

[0095] In some embodiments, the effector domain is indirectly fused to the targeting domain via a peptide linker, hi some embodiments, the effector domain is indirectly fused to the targeting domain via a peptide linker of sufficient length to allow the effector domain and the targeting domain to simultaneously bind to their respective target proteins.

[0096] In some embodiments, the effector domain is fused to the C-terminus of the targeting domain. In some embodiments, the effector moiety is fused to the N-terminus of the targeting domain.

[0097] In one aspect, the present invention provides a nucleic acid molecule encoding the fusion protein described herein.In some embodiments, the nucleic acid molecule is a DNA molecule.In some embodiments, the nucleic acid molecule is an RNA molecule.

[0098] In one aspect, provided herein is a vector comprising a nucleic acid molecule described herein. In some embodiments, the vector is a plasmid or a viral vector.

[0099] In one aspect, provided herein is a viral particle comprising a nucleic acid described herein.

[0100] In one aspect, described herein is an in vitro cell or cell population comprising a fusion protein described herein, a nucleic acid molecule described herein, or a vector described herein.

[0101] In one aspect, provided herein is a pharmaceutical composition comprising a fusion protein described herein, a nucleic acid molecule described herein, a vector described herein, or a viral particle described herein, and an excipient.

[0102] In one aspect, provided herein is a method of producing a fusion protein described herein, comprising: (a) introducing into a cell or cell population in vitro a nucleic acid described herein, a vector described herein, or a viral particle described herein; (b) culturing the cell or cell population in a culture medium under conditions suitable for expression of the fusion protein; (c) isolating the fusion protein from the culture medium; and (d) optionally purifying the fusion protein.

[0103] In one aspect, provided herein is a method of treating a disease in a subject comprising administering to a subject in need thereof a fusion protein described herein, a nucleic acid described herein, a vector described herein, or a viral particle described herein, or a pharmaceutical composition described herein.

[0104] In some embodiments, the subject is a human.

[0105] In some embodiments, the disease is associated with decreased expression of a functional version of a membrane protein compared to unaffected controls.

[0106] In some embodiments, the disease is associated with decreased stability of a functional version of a membrane protein compared to an unaffected control.

[0107] In some embodiments, the disease is associated with increased ubiquitination and degradation of membrane proteins compared to unaffected controls.

[0108] In some embodiments, the disease is a genetic disease.

[0109] In some embodiments, the disease is GLUT1 deficiency syndrome, recurrent paroxysmal kinesigenic dyskinesia 1, Usher syndrome type 2A, early infantile epileptic encephalopathy type 9, tuberous sclerosis type 2; tuberous sclerosis type 1, KCNQ2-related disorders (e.g., epileptic encephalopathy), Becker muscular dystrophy, autosomal dominant RP, Alagille syndrome 1, and Gillespie syndrome.

[0110] In some embodiments, the disease is selected from the group consisting of early infantile epileptic encephalopathy type 11, early infantile epileptic encephalopathy type 13, early infantile epileptic encephalopathy type 27, cystic fibrosis, Dravet syndrome, Wilson's disease, recurrent ataxia type 2; epilepsy (e.g., focal with speech impairment and with or without mental retardation), myoclonic-astatic epilepsy, alternating hemiplegia of childhood, alternating hemiplegia of childhood type 2, epilepsy type 7, GABRB3-related epilepsy, and KCNQ2-related disorders (e.g., epileptic encephalopathy).

[0111] In some embodiments, the disease is selected from the group consisting of GRIN2B-related disorders, early infantile epileptic encephalopathy type 9, early infantile epileptic encephalopathy type 11, early infantile epileptic encephalopathy type 13, early infantile epileptic encephalopathy type 27, cystic fibrosis, Dravet syndrome, Wilson's disease, recurrent paroxysmal ataxia type 2; GLUT1 deficiency syndrome, recurrent paroxysmal kinesigenic dyskinesia 1, epilepsy (e.g., focal with speech impairment and with or without mental retardation), myoclonic-astatic epilepsy, Usher syndrome type 2A, alternating hemiplegia of childhood, alternating hemiplegia of childhood type 2, epilepsy type 7, GABRB3-associated epilepsy; tuberous sclerosis type 2; tuberous sclerosis type 1, Becker muscular dystrophy, autosomal dominant RP, Alagille syndrome 1, and Gillespie syndrome.

[0112] In some embodiments, the disease is a haploinsufficiency disease.

[0113] In some embodiments, the fusion protein is administered in a therapeutically effective dose.

[0114] In some embodiments, the fusion protein is administered systemically or locally.

[0115] In some embodiments, the fusion protein is administered intravenously, subcutaneously, or intramuscularly.

[0116] In one aspect, the present invention provides a nucleic acid molecule encoding the fusion protein described herein.In some embodiments, the nucleic acid molecule is a DNA molecule.In some embodiments, the nucleic acid molecule is an RNA molecule.

[0117] In one aspect, provided herein is a vector comprising a nucleic acid molecule described herein. In some embodiments, the vector is a plasmid or a viral vector.

[0118] In one aspect, provided herein is a viral particle comprising a nucleic acid described herein.

[0119] In one aspect, described herein is an in vitro cell or cell population comprising a fusion protein described herein, a nucleic acid molecule described herein, or a vector described herein.

[0120] In one aspect, provided herein is a pharmaceutical composition comprising a fusion protein described herein, a nucleic acid molecule described herein, a vector described herein, or a viral particle described herein, and an excipient.

[0121] In one aspect, provided herein is a method of producing a fusion protein described herein, comprising: (a) introducing into a cell or cell population in vitro a nucleic acid described herein, a vector described herein, or a viral particle described herein; (b) culturing the cell or cell population in a culture medium under conditions suitable for expression of the fusion protein; (c) isolating the fusion protein from the culture medium; and (d) optionally purifying the fusion protein.

[0122] In one aspect, provided herein is a method of treating a disease in a subject comprising administering to a subject in need thereof a fusion protein described herein, a nucleic acid described herein, a vector described herein, or a viral particle described herein, or a pharmaceutical composition described herein.

[0123] In some embodiments, the subject is a human.

[0124] In some embodiments, the disease is associated with decreased expression of a functional version of the membrane protein compared to unaffected controls.

[0125] In some embodiments, the disease is associated with decreased stability of a functional version of the membrane protein compared to non-diseased controls.

[0126] In some embodiments, the disease is associated with increased ubiquitination and degradation of membrane proteins compared to unaffected controls.

[0127] In some embodiments, the disease is a genetic disease.

[0128] In some embodiments, the disease is early infantile epileptic encephalopathy type 2, Wilson's disease, early infantile epileptic encephalopathy type 4, mental retardation autosomal dominant 5, aphasia, Alagille syndrome 1, epilepsy, tuberous sclerosis complex-2, tuberous sclerosis complex-1, KIF1A-associated neurological disorder, encephalopathy, Phelan-McDermid syndrome, Becker muscular dystrophy, RP1, retinitis pigmentosa 1, dilated cardiomyopathy 1G, DYNC1H1 syndrome, TRIO-associated intellectual disability (ID), and USP9X developmental disorder.

[0129] The method of any one of claims 43 to 48, wherein the disease is early infantile epileptic encephalopathy type 2, Wilson's disease, early infantile epileptic encephalopathy type 4, mental retardation autosomal dominant 5, primary progressive aphasia and FTD (frontotemporal degeneration), Alagille syndrome 1, familial focal epilepsy showing various foci 1, tuberous sclerosis complex-2, tuberous sclerosis complex-1, KIF1A-associated neurological disorder, encephalopathy, Phelan-McDermid syndrome, Becker muscular dystrophy, RP1, retinitis pigmentosa 1, dilated cardiomyopathy 1G, DYNC1H1 syndrome, TRIO-associated intellectual disability (ID), and USP9X developmental disorder.

[0130] In some embodiments, the disease is a haploinsufficiency disease.

[0131] In some embodiments, the fusion protein is administered in a therapeutically effective dose.

[0132] In some embodiments, the fusion protein is administered systemically or locally.

[0133] In some embodiments, the fusion protein is administered intravenously, subcutaneously, or intramuscularly. [Brief explanation of the drawings]

[0134] [Figure 1]1A-1D provide schematic diagrams of exemplary fusion proteins described herein. FIG. 1A is a schematic diagram of an engineered deubiquitinase comprising, at its N'- to C'-terminus, a VHH that specifically binds a membrane-targeted protein and a catalytic domain of a deubiquitinase. In this specific embodiment, the C-terminus of the VHH is directly linked to the N-terminus of the catalytic domain of the deubiquitinase. FIG. 1B is a schematic diagram of an engineered deubiquitinase comprising, at its N'- to C'-terminus, a catalytic domain of a deubiquitinase that specifically binds a membrane-targeted protein and a VHH that specifically binds a membrane-targeted protein. In this specific embodiment, the C-terminus of the catalytic domain of the deubiquitinase is directly linked to the N-terminus of the VHH. FIG. 1C is a schematic diagram of an engineered deubiquitinase comprising, at its N'- to C'-terminus, a VHH that specifically binds a membrane-targeted protein and a catalytic domain of a deubiquitinase. In this specific embodiment, the C-terminus of the VHH is indirectly connected to the N-terminus of the catalytic domain of a deubiquitinase via a peptide linker. Figure ID is a schematic diagram of an engineered deubiquitinase comprising a catalytic domain of a deubiquitinase that specifically binds to a membrane-targeted protein from its N' to C' terminus and a VHH that specifically binds to a membrane-targeted protein. In this specific embodiment, the C-terminus of the catalytic domain of the deubiquitinase is indirectly connected to the N-terminus of the VHH via a peptide linker. [Figure 2] FIG. 1 is a schematic diagram of the assay utilized in Example 3 to screen the effect of targeted deubiquitination of different membrane proteins on target protein expression. [Figure 3] 1 is a bar graph showing the fold change in KCNQ1 protein expression compared to the control (indicated). [Figure 4] 1 is a bar graph showing the fold change in SCN1A protein expression compared to the control (indicated). [Figure 5] 1 is a bar graph showing the fold change in GRIN2B protein expression compared to the control (indicated). [Figure 6]FIG. 1 is a bar graph showing the fold change in SLC50A1 protein expression compared to the control (deubiquitinase without nanobody targeting the alpha-tag). [Figure 7] 1 is a bar graph showing the fold change in TREM258 protein expression compared to the control (deubiquitinase without nanobody targeting the alpha-tag). [Figure 8] FIG. 1 is a bar graph showing the fold change in FSHR protein expression compared to the control (deubiquitinase without nanobody targeting the alpha-tag). DETAILED DESCRIPTION OF THE INVENTION

[0135] 5. Detailed Description 5.1 Overview Ubiquitination is a process in which ubiquitin ligases mediate the addition of ubiquitin, a 76-amino acid regulatory protein, to substrate proteins. Ubiquitination typically begins with the attachment of a single ubiquitin molecule to a lysine amino acid residue on the substrate protein. (Mevissen T. et al. Mechanisms of Deubiquitinase Specificity and Regulation Annual Review of Biochemistry 86:1, 159-192 (2017), the entire contents of which are incorporated herein by reference.) These monoubiquitination events are abundant and serve a variety of functions. Ubiquitin itself contains seven lysine residues, all of which can be ubiquitinated, resulting in polyubiquitinated proteins. Komander, D. et al. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10, 550-563 (2009), the entire contents of which are incorporated herein by reference. Mono- and polyubiquitination can have multiple effects on substrate proteins, including marking the substrate protein for degradation via the proteasome, changing the cellular location of the protein, changing the activity of the protein, and / or promoting or preventing normal protein interactions. See, for example, Hershko A. et al. The ubiquitin system. Annu Rev Biochem. 67:425-79 (1998); Nandi D, et al. The ubiquitin-proteasome system. J Biosci. Mar;31(1):137-55 (2006), the entire contents of each of which are incorporated herein by reference. The effects of ubiquitination can be reversed or prevented by removing the ubiquitin protein from the substrate protein. The removal of ubiquitin from substrate proteins is mediated by deubiquitinase (DUB) proteins.

[0136] Many genetic disorders are associated with or caused by a decrease in the expression level or stability of functional membrane proteins. For example, haploinsufficiency genetic disorders are caused by the presence of a single copy of a wild-type allele heterozygously combined with a loss-of-function variant allele, and the level of expressed functional protein is insufficient to produce a normal phenotype. See, for example, Johnson, A. et al., Causes and effects of haploinsufficiency. Biol Rev, 94: 1774-1785 (2019), the entire contents of which are incorporated herein by reference. Haploinsufficiency can result from de novo or inherited loss-of-function mutations in the variant allele, resulting in little or no functional protein production. Other genetic disorders result from the ubiquitination and subsequent degradation of the variant but functional protein, resulting in a decrease in functional protein expression.

[0137] The present disclosure provides, inter alia, novel fusion proteins comprising a catalytic domain of a deubiquitinase (or a functional fragment thereof) and a targeting moiety, such as a VHH, that specifically binds to a target membrane protein. In some embodiments, a decrease in the expression of a functional version of the target membrane protein or a decrease in the stability of a functional version of the target membrane protein is associated with a disease phenotype. As such, the fusion proteins described herein are particularly useful for treating genetic diseases characterized by a decrease in the expression level of a functional target membrane protein or the stability of the target membrane protein. Upon expression of the fusion protein by a host cell, the catalytic domain of the deubiquitinase is specifically targeted to and deubiquitinates the target membrane protein, resulting in an increase in the expression of the target membrane protein to a level sufficient to, for example, alleviate a disease phenotype.

[0138] 5.2 Definition The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.

[0139] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which this disclosure pertains.For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary of Biochemistry and Molecular Biology, Revised, 2000, Oxford University Press provide those skilled in the art with a general dictionary of many of the terms used in this disclosure.

[0140] It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the claimed subject matter. In this application, the use of the singular includes the plural unless specifically stated otherwise.

[0141] It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Furthermore, the use of the term "including" as well as other forms such as "include," "includes," and "included" is not limiting.

[0142] Whenever an embodiment is described herein using the word "comprising," it is understood that other similar embodiments described by "consisting of" and / or "consisting essentially of" are also provided.

[0143] The term "and / or" as used herein should be interpreted as a specific disclosure of two specific features or components, each with or without the other. Thus, when used in phrases such as "A and / or B" herein, the term "and / or" is intended to include "A and B," "A or B," "A" (single), and "B" (single). Similarly, when used in phrases such as "A, B, and / or C," the term "and / or" is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (single); B (single); and C (single).

[0144] Units, prefixes, and symbols are denoted in the format adopted by the International System of Units (SI). Numerical ranges are inclusive of the numbers defining the range. The headings provided herein are not intended to limit the various aspects of the disclosure, which can be had by reference to the specification in its entirety. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.

[0145] As described herein, any concentration range, percentage range, ratio range, or integer range should be understood to include any integer value within the stated range, and fractions thereof, where appropriate (such as integer tenths and hundredths), unless otherwise indicated.

[0146] The terms "about" or "essentially consisting of" refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which depends in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system. For example, "about" or "essentially consisting of" can mean within one or more standard deviations, as practiced in the art. Alternatively, "about" or "essentially consisting of" can mean a range of up to 20%. Furthermore, particularly with respect to biological systems or processes, these terms can mean up to an order of magnitude difference from the value or up to five times the value. When specific values ​​or compositions are provided in the applications and claims, unless otherwise stated, the meaning of "about" or "essentially consisting of" should be assumed to be within an acceptable error range for that particular value or composition.

[0147] As used herein, the term "catalytic domain" with respect to a deubiquitinating enzyme refers to the amino acid sequence of the deubiquitinating enzyme, or a variant thereof, that is capable of mediating deubiquitination of a target protein. The catalytic domain may comprise the naturally occurring amino acid sequence of the deubiquitinating enzyme, or it may comprise a variant amino acid sequence of the naturally occurring deubiquitinating enzyme. The catalytic domain may comprise the minimal amino acid sequence of the deubiquitinating enzyme to mediate deubiquitination of a target protein. The catalytic domain may comprise a larger than minimal amino acid sequence of the deubiquitinating enzyme to mediate deubiquitination of a target protein.

[0148] The terms "polynucleotide" and "nucleic acid sequence" are used interchangeably herein and refer to a polymer of DNA or RNA. Polynucleotide sequences can be single- or double-stranded; contain natural, non-natural, or modified nucleotides; and contain natural, non-natural, or modified internucleotide linkages, such as phosphoramidate or phosphorothioate linkages instead of the phosphodiesters found between nucleotides in unmodified polynucleotide sequences. Polynucleotide sequences include, but are not limited to, all polynucleotide sequences obtained by any means available in the art, including, but not limited to, recombinant means, such as cloning polynucleotide sequences from recombinant libraries or cell genomes, using conventional cloning techniques and polymerase chain reaction, etc., as well as by synthetic means.

[0149] The terms "amino acid sequence" and "polypeptide" are used interchangeably herein to refer to a polymer of amino acids joined by one or more peptide bonds.

[0150] The term "functional variant" as used herein with respect to a protein or polypeptide refers to a protein that contains at least one amino acid modification (e.g., substitution, deletion, addition) compared to the amino acid sequence of a reference protein that retains at least one particular function. In some embodiments, the reference protein is a wild-type protein. For example, a functional variant of an IL-2 protein can refer to an IL-2 protein that contains an amino acid substitution compared to the wild-type IL-2 protein that retains the ability to bind to the intermediate-affinity IL-2 receptor but eliminates the protein's ability to bind to the high-affinity IL-2 receptor. Not all functions of the reference wild-type protein need be retained by a functional variant of a protein. In some cases, one or more functions are selectively reduced or eliminated.

[0151] The term "functional fragment" as used herein in relation to a protein or polypeptide refers to a fragment of a reference protein that retains at least one specific function. For example, a functional fragment of an anti-HER2 antibody may refer to a fragment of an anti-HER2 antibody that retains the ability to specifically bind to HER2 antigen. Not all functions of the reference protein need to be retained by a functional fragment of a protein. In some cases, one or more functions are selectively reduced or eliminated.

[0152] As used herein, the term "modified" with respect to a polynucleotide sequence refers to a polynucleotide sequence that contains at least one substitution, alteration, inversion, addition, or deletion of a nucleotide compared to a reference polynucleotide sequence. A modification can include a non-naturally occurring nucleotide. As used herein, the term "modified" with respect to an amino acid sequence refers to an amino acid sequence that contains at least one substitution, alteration, inversion, addition, or deletion of an amino acid residue compared to a reference amino acid sequence. A modification can include the inclusion of a non-naturally occurring amino acid residue.

[0153] As used herein, the term "derived" with respect to an amino acid sequence refers to an amino acid sequence that has at least 80% sequence identity with a reference naturally occurring amino acid sequence. For example, a catalytic domain derived from a naturally occurring deubiquitinase means that the catalytic domain has an amino acid sequence that has at least 80% sequence identity with the sequence of the deubiquitinase catalytic domain from which it is derived. The term "derived" as used herein does not refer to any particular process or method for obtaining the amino acid sequence. For example, the amino acid sequence may be chemically synthesized or recombinantly synthesized.

[0154] The term "fusion protein" and grammatical equivalents, as used herein, refer to a protein comprising an amino acid sequence derived from at least two separate proteins. The amino acid sequences of the at least two separate proteins may be directly connected via a peptide bond; or may be operably connected via an amino acid linker. Thus, the term fusion protein encompasses embodiments in which, for example, the amino acid sequence of protein A is directly connected to the amino acid sequence of protein B via a peptide bond (protein A-protein B), as well as embodiments in which, for example, the amino acid sequence of protein A is operably connected to the amino acid sequence of protein B via an amino acid linker (protein A-linker-protein B).

[0155] The term "fused" and its grammatical equivalents, as used herein, refers to the operative connection of an amino acid sequence derived from one protein to an amino acid sequence derived from a different protein. The term fused encompasses both the direct connection of two amino acid sequences via a peptide bond and the indirect connection via an amino acid linker.

[0156] An "isolated antibody" refers to an antibody that is substantially free of other antibodies with different antigenic specificities (e.g., an isolated antibody that specifically binds to HER2 is substantially free of antibodies that specifically bind to antigens other than HER2). However, an isolated antibody that specifically binds to HER2 may cross-react with other antigens, such as HER2 molecules from different species. Moreover, an isolated antibody may be substantially free of other cellular material and / or chemicals. In comparison, an "isolated" nucleic acid refers to a substance whose nucleic acid composition is significantly different, i.e., has a chemical identity, properties, and utility distinct from those of nucleic acids found in nature. For example, unlike native DNA, isolated DNA is an independent piece of native DNA and is not an integral part of the larger structural complex, chromosome, in which it is found in nature. Furthermore, unlike native DNA, isolated DNA can be used as a PCR primer or hybridization probe to measure gene expression and detect biomarker genes or mutations to, among other things, diagnose disease or predict the effectiveness of therapeutic drugs. The isolated nucleic acid may also be purified using standard techniques well known in the art so that it is substantially free of other cellular components or other contaminants, such as other cellular nucleic acids or proteins.

[0157] As used herein, the term "antibody" or "antibodies" is used in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments (i.e., antigen-binding fragments as defined herein), so long as they exhibit the desired antigen-binding activity. Thus, the term antibody includes, for example, full-length antibodies, antigen-binding fragments of full-length antibodies, molecules comprising antibody CDRs, VH regions, and / or VL regions; and antibody-like scaffolds (e.g., fibronectin). Examples of antibodies include monoclonal antibodies, recombinantly produced antibodies, monospecific antibodies, multispecific antibodies (including bispecific antibodies), human antibodies, humanized antibodies, chimeric antibodies, immunoglobulins, synthetic antibodies, tetrameric antibodies comprising two heavy chain and two light chain molecules, antibody light chain monomers, antibody heavy chain monomers, antibody light chain dimers, antibody heavy chain dimers, antibody light chain-antibody heavy chain pairs, intrabodies, heteroconjugate antibodies, antibody-drug conjugates, single domain antibodies (e.g., VHH, (VHH)2), monovalent antibodies, single chain antibodies, single chain Fvs (scFv; (scFv)2), camelized antibodies, affybodies, Fab fragments (e.g., Fab, single chain Fab (scFab), F(ab')2 fragments, disulfide-linked Fvs (sdFv), anti-idiotypic (anti-Id) antibodies (e.g., anti-anti-Id antibodies, Antibodies include, but are not limited to, antibodies, diabodies, tribodies, and antibody-like scaffolds (e.g., fibronectin), Fc fusions (e.g., Fab-Fc, scFv-Fc, VHH-Fc, (scFv)2-Fc, (VHH)2-Fc, and antigen-binding fragments of any of the above, as well as conjugates or fusion proteins comprising any of the above. In certain embodiments, antibodies described herein refer to polyclonal antibody populations. In certain embodiments, antibodies described herein refer to monoclonal antibody populations. Antibodies may be of any type (e.g., IgG, IgE, IgM, IgD, IgA, or IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2), or any subclass (e.g., IgG 2a or IgG2b ) immunoglobulin (Ig) molecules. In certain embodiments, the antibodies described herein are IgG antibodies, or classes (e.g., human IgG1 or IgG4) or subclasses thereof. In specific embodiments, the antibodies are humanized monoclonal antibodies. In another specific embodiment, the antibodies are human monoclonal antibodies.

[0158] The term "full-length antibody," as used herein, refers to an antibody having a structure substantially similar to that of a native antibody, comprising two heavy chains and two light chains interconnected by disulfide bonds. In some embodiments, the two heavy chains comprise substantially identical amino acid sequences; the two light chains comprise substantially identical amino acid sequences. Antibody chains can be substantially identical, but not completely identical, if they differ due to post-translational modifications such as C-terminal truncation of lysine residues, alternative glycosylation patterns, etc.

[0159] The terms "antigen-binding fragment" and "antigen-binding domain" are used interchangeably herein and refer to one or more polypeptides other than a full-length antibody, which polypeptide is capable of specifically binding to an antigen and includes a portion of a full-length antibody (e.g., VH, VL). Exemplary antigen-binding fragments include, but are not limited to, single-domain antibodies (e.g., VHH, (VHH)2), single-chain antibodies, single-chain Fvs (scFv; (scFv)2), camelized antibodies, affibodies, Fab fragments (e.g., Fab, single-chain Fab (scFab), F(ab')2 fragments, and disulfide-linked Fvs (sdFv). An antigen-binding domain may be part of a larger protein, such as a full-length antibody.

[0160] The term "(scFv)2" as used herein refers to an antibody comprising a first and a second scFv operably connected (e.g., via a linker). The first and second scFvs can specifically bind to the same or different antigens. In some embodiments, the first and second scFvs are operably connected by an amino acid via an amino acid linker.

[0161] The term "(VHH)2" as used herein refers to an antibody comprising a first and a second VHH that are operably connected (e.g., via a linker). The first and second VHHs can specifically bind to the same or different antigens. In some embodiments, the first and second VHHs are operably connected by an amino acid via an amino acid linker.

[0162] The term "Fab-Fc," as used herein, refers to an antibody comprising a Fab operably linked to an Fc domain or a subunit of an Fc domain. The full-length antibodies described herein comprise two Fabs, one Fab operably linked to one Fc domain and the other Fab operably linked to a second Fc domain.

[0163] The term "scFv-Fc," as used herein, refers to an antibody comprising an scFv operably linked to an Fc domain or a subunit of an Fc domain.

[0164] The term "VHH-Fc", as used herein, refers to an antibody comprising a VHH operably linked to an Fc domain or a subunit of an Fc domain.

[0165] The term "(scFv)2-Fc," as used herein, refers to an (scFv)2 operably linked to an Fc domain or a subunit of an Fc domain.

[0166] The term "(VHH)2-Fc," as used herein, refers to a (VHH)2 operably linked to an Fc domain or a subunit of an Fc domain.

[0167] "Antibody-like scaffolds" are known in the art; for example, fibronectin and designed ankyrin repeat proteins (DARPins) have been used as scaffolds to replace antigen-binding domains. See, for example, Gebauer and Skerra, Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13:245-255 (2009) and Stumpp et al., Darpins: A new generation of protein therapeutics. Drug Discovery Today 13:695-701 (2008). Exemplary antibody-like scaffold proteins include, but are not limited to, lipocalins (Anticalins), Protein A-derived molecules such as the Z domain (Affibody), A domain (Avimer / Maxibody) of Protein A, serum transferrin (trans-body); designed ankyrin repeat proteins (DARPins), VNAR fragments, fibronectin (AdNectin), C-type lectin domains (tetranectins); the variable domain of the novel antigen receptor beta-lactamase (VNAR fragment), human gamma-crystallin or ubiquitin (Affilin molecules); Kunitz-type domains of human protease inhibitors, microbodies such as proteins from the knottin family, peptide aptamers and fibronectin (Adnectin).

[0168] As used herein, the term "CDR" or "complementarity-determining region" refers to the discontinuous antigen-binding sites found within the variable regions of both heavy and light chain polypeptides. These particular regions are described by Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977) and Kabat et al., Sequences of proteins of immunological interest. (1991), all of which are incorporated herein by reference in their entireties. Unless otherwise specified, the term "CDR" refers to a CDR as defined by Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977) and Kabat et al., Sequences of proteins of immunological interest. (1991).

[0169] As used herein, the term "framework (FR) amino acid residues" refers to amino acids in the framework region of an antibody variable region. The term "framework region" or "FR region" as used herein includes amino acid residues that are part of the variable region but are not part of the CDRs (e.g., using the Kabat definition of CDRs).

[0170] As used herein, the term "heavy chain," when used in reference to an antibody, can refer to any of the distinct types, e.g., alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ), which include the subclasses of IgG, e.g., IgG1, IgG2, IgG3, and IgG4, based on the amino acid sequence of the constant domain, and give rise to antibodies of the IgA, IgD, IgE, IgG, and IgM classes, respectively.

[0171] As used herein, the term "light chain," when used in reference to an antibody, can refer to any distinct type, e.g., kappa (κ) or lambda (λ), based on the amino acid sequence of the constant domain. Light chain amino acid sequences are well known in the art. In a specific embodiment, the light chain is a human light chain.

[0172] As used herein, the term "variable region" refers to a portion of an antibody, generally a portion of either the light or heavy chain, typically the amino-terminal approximately 110-120 amino acids or 110-125 amino acids in the mature heavy chain and approximately 90-115 amino acids in the mature light chain, which differ extensively in sequence among antibodies and are used to determine the binding and specificity of a particular antibody for its particular antigen. Sequence variability is concentrated in regions called complementarity-determining regions (CDRs), whereas the more highly conserved regions in the variable domain are called framework regions (FRs). While not wishing to be bound by a particular mechanism or theory, the CDRs of the light and heavy chains are primarily responsible for the interaction and specificity of the antibody with its antigen. In certain embodiments, the variable region is a human variable region. In certain embodiments, the variable region comprises rodent or murine CDRs and human framework regions (FRs). In certain embodiments, the variable region is a primate (e.g., non-human primate) variable region. In certain embodiments, the variable region comprises rodent or murine CDRs and primate (e.g., non-human primate) framework regions (FR).

[0173] The terms "VL" and "VL domain" are used interchangeably to refer to the light chain variable region of an antibody.

[0174] The terms "VH" and "VH domain" are used interchangeably to refer to the heavy chain variable region of an antibody.

[0175] As used herein, the terms "constant region" and "constant domain" are interchangeable and are common in the art. The constant region is the carboxyl-terminal portion of an antibody portion, e.g., the light chain and / or heavy chain, that is not directly involved in binding the antibody to an antigen but can exhibit various effector functions, such as interaction with Fc receptors (e.g., Fc gamma receptors). The constant region of an immunoglobulin (Ig) molecule generally has a more conserved amino acid sequence than the immunoglobulin (Ig) variable domain.

[0176] The term "Fc region," as used herein, refers to the C-terminal region of an immunoglobulin (Ig) heavy chain comprising, from N- to C-terminus, at least a CH2 domain operably connected to a CH3 domain. In some embodiments, the Fc region comprises an immunoglobulin (Ig) hinge region operably connected to the N-terminus of the CH2 domain. Examples of proteins with engineered Fc regions can be found in Saunders 2019 (KO Saunders, "Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life," 2019, Frontiers in Immunology, Vol. 10, Art. 1296, pp. 1-20, incorporated herein by reference).

[0177] As used herein, the term "EU numbering system" refers to the EU numbering convention for antibody constant regions as described in Edelman, GM et al., Proc. Natl. Acad. USA, 63, 78-85 (1969) and Kabat et al., Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, 5th edition, 1991, each of which is incorporated herein by reference in its entirety.

[0178] As used herein, the term "Kabat numbering system" refers to the Kabat numbering convention for antibody variable regions. See, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, 5th edition, 1991. Unless otherwise noted, the numbering of antibody variable regions is indicated by the Kabat numbering system.

[0179] As used herein, the term "specifically binds to" refers to a molecule that binds to an antigen (e.g., an epitope or immune complex), and such binding is understood by those of skill in the art. For example, a molecule that specifically binds to an antigen may generally bind with lower affinity to other peptides or polypeptides, as determined, for example, by immunoassay, BIAcore®, KinExA 3000 instrument (Sapidyne Instruments, Boise, ID), or other assays known in the art. In specific embodiments, molecules that specifically bind to an antigen have a K that is lower than the K that these molecules have when nonspecifically binding to another antigen. A K at least 2 logs (e.g., a factor of 10), 2.5 logs, 3 logs, 4 logs, or more A The antibody binds to an antigen at a specific region. Those skilled in the art will recognize that the antibody described herein may specifically bind to more than one antigen (e.g., via different regions of the antibody molecule). The term "specifically binds" includes molecules that cross-react with the same antigen of different species. For example, an antigen-binding domain that specifically binds to human CD20 may cross-react with CD20 of another species (e.g., cynomolgus monkey, or mouse) and still be considered herein to specifically bind to human CD20.

[0180] "Affinity" refers to the total strength of non-covalent interactions between a single binding site of a molecule (e.g., a receptor) and its binding partner (e.g., a ligand). Unless otherwise indicated, "binding affinity" as used herein refers to the intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antigen-binding moiety and an antigen, or a receptor and its ligand). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD), which is the ratio of the dissociation rate constant to the association rate constant (koff and kon, respectively). Thus, equivalent affinities can involve different rate constants as long as the ratio of the rate constants remains the same. Affinity can be measured by established methods known in the art, including those described herein. A particular method for measuring affinity is surface plasmon resonance (SPR).

[0181] Determining "percent identity" between two sequences (e.g., amino acid sequences or nucleic acid sequences) can be accomplished using a mathematical algorithm. Identity measures the percent of identical matches between the smaller of two or more sequences, with gap alignment (if any) addressed by a particular mathematical model or computer program (i.e., "algorithm"). A specific, non-limiting example of a mathematical algorithm utilized for comparing two sequences is the algorithm of Karlin S & Altschul SF (1990) PNAS 87: 2264-2268, modified as in Karlin S & Altschul SF (1993) PNAS 90: 5873-5877, each of which is incorporated herein by reference in its entirety. Such an algorithm is incorporated into the BLASTN, BLASTP, and BLASTX programs of Altschul SF et al., (1990) J Mol Biol 215: 403, which are incorporated herein by reference in their entirety. BLAST nucleotide searches can be performed using the NBLAST nucleotide program parameters, for example, score=100, word length=12, to obtain nucleotide sequences homologous to the nucleic acid molecules described herein. BLAST protein searches can be performed using the BLASTP program parameters, for example, with default settings, to obtain amino acid sequences homologous to the protein molecules described herein. Gapped BLAST can be used to obtain gapped alignments for comparison purposes, as described in Altschul SF et al., (1997) Nuc Acids Res 25: 3389-3402, the entire contents of which are incorporated herein by reference. Alternatively, PSI BLAST can be used to perform an iterated search that detects distant relationships between molecules (ibid.).When utilizing BLAST, Gapped BLAST, and PSI Blast programs, the default parameters of the respective programs (e.g., BLASTP and BLASTN) can be used (see, for example, the National Center for Biotechnology Information (NCBI) World Wide Web at ncbi.nlm.nih.gov). Another specific, non-limiting example of a mathematical algorithm utilized for comparing sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11-17, which is incorporated herein by reference in its entirety. Such an algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When utilizing the ALIGN program to compare amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically, only exact matches are counted. As mentioned above, identity percentage is based on the amino acid match between the smaller of the two proteins.Therefore, for example, using NCBI Basic Local Alignment Tool-BLASTP program with default settings (search parameters: word size 3, expectation value 0.05, hit list 100, gap cost 11,1; matrix BLOSUM62, filter string: F; genetic code: 1; window size: 40; threshold: 11; composition-based statistics: 2; Karlin-Altschul statistics: lambda: 0.31293; 0.267; K: 0.132922; 0.041; H: 0.401809; 0.14; and relative statistics: effective search space: 288906), the identity percentage between SEQ ID NO: 80 and SEQ ID NO: 293 is 100% identity.

[0182] As used herein, the term "operably linked" refers to the association of polynucleotide or amino acid sequence elements in a functional relationship. For example, a polynucleotide sequence is operably connected when it is placed into a functional relationship with another polynucleotide sequence. In some embodiments, a transcriptional regulatory polynucleotide sequence, such as a promoter, enhancer, or other expression control element, is operably linked to a protein-encoding polynucleotide sequence if it affects the transcription of the protein-encoding polynucleotide sequence.

[0183] The terms "subject" and "patient" are used interchangeably herein and include any human or non-human animal. The term "non-human animal" includes, but is not limited to, vertebrates such as non-human primates, sheep, dogs, and rodents such as mice, rats, and guinea pigs. In some embodiments, the subject is a human.

[0184] As used herein, the term "administering" refers to the physical introduction of a therapeutic agent (or a precursor of a therapeutic agent that is metabolized or transformed in the subject's body to produce a therapeutic agent in vivo) into a subject using any of a variety of methods and delivery systems known to those of skill in the art. Exemplary routes include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal, or other parenteral routes of administration, for example, by injection or infusion. The term "parenteral administration," as used herein, refers to modes of administration other than enteral and topical administration, usually by injection, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion, as well as in vivo electroporation. Therapeutic agents may be administered via non-parenteral routes or orally. Other non-parenteral routes include topical, epidermal, or mucosal routes of administration, e.g., intranasal, vaginal, rectal, sublingual, or topical. Administration can also be, for example, single, multiple, and / or over one or more extended periods.

[0185] A "therapeutically effective amount" or "therapeutically effective dose" of a drug or therapeutic agent is any amount of drug that, when used alone or in combination with another therapeutic agent, protects a subject from onset of disease or promotes regression of the disease, as evidenced by a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease-free symptom intervals, or prevention of functional impairment or disability due to the affliction of the disease. The ability of a therapeutic agent to promote regression of the disease can be evaluated using a variety of methods known to those of skill in the art, for example, by assaying the activity of the agent in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or in in vitro assays.

[0186] The terms "disease," "disorder," and "syndrome" are used interchangeably herein.

[0187] As used herein, the terms "treat," "treating," "treatment," and the like refer to alleviating or ameliorating a disease and / or its associated symptoms, or achieving a desired pharmacological and / or physiological effect. It is recognized that treating a disease does not require, but does not preclude, the complete disappearance of the disease or its associated symptoms. In some embodiments, the effect is therapeutic, i.e., the effect partially or completely reduces, reduces, counteracts, alleviates, relieves, reduces the intensity of, or cures the disease and / or adverse symptoms that may result from the disease, but is not limited to this. In some embodiments, the effect is prophylactic, i.e., the effect prevents or prevents the occurrence or recurrence of the disease. To this end, the methods disclosed herein comprise administering a therapeutically effective amount of a composition described herein.

[0188] 5.3 Fusion proteins In certain aspects, provided herein are fusion proteins comprising an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof; and a targeting domain comprising a moiety that specifically binds to a target cytosolic protein.

[0189] 5.3.1 Effector domain In some embodiments, the effector domain comprises a catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof. In some embodiments, the deubiquitinase is human. In some embodiments, the catalytic domain is derived from a naturally occurring deubiquitinase (e.g., a naturally occurring human deubiquitinase).

[0190] In some embodiments, the amino acid sequence of the effector domain comprises the amino acid sequence of a full-length deubiquitinase, hi some embodiments, the amino acid sequence of the effector domain comprises the amino acid sequence of a catalytic domain of a deubiquitinase and additional amino acid sequences at the N-terminus, C-terminus, or N-terminus and C-terminus of the catalytic domain.

[0191] In some embodiments, the catalytic domain comprises the native amino acid sequence of a deubiquitinase. In some embodiments, the catalytic domain comprises a variant of a native deubiquitinase. In some embodiments, the amino acid sequence of the catalytic domain of the fusion protein is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of a native deubiquitinase. In some embodiments, the amino acid sequence of the catalytic domain of the fusion protein comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 amino acid modifications compared to the amino acid sequence of the catalytic domain of a native deubiquitinase.

[0192] In some embodiments, the catalytic domain comprises the minimal amino acid sequence of a naturally occurring deubiquitinase sufficient to mediate deubiquitination of a target protein, hi some embodiments, the catalytic domain comprises a larger than minimal amino acid sequence of a naturally occurring deubiquitinase sufficient to mediate deubiquitination of a target protein.

[0193] In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease or a metalloprotease. In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease. In some embodiments, the deubiquitinating enzyme is a metalloprotease. In some embodiments, the deubiquitinating enzyme is a ubiquitin-specific protease (USP), a ubiquitin C-terminal hydrolase (UCH), a Machado-Josephine domain protease (MJD), an ovarian tumor protease (OTU), a MINDY protease, or a ZUFSP protease.

[0194] Exemplary deubiquitinating enzymes include USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, USP46, USP47, USP48, USP49, USP50, USP51, USP52, USP53, USP54, USP55, USP56, USP57, USP58, USP59, USP60, USP61, USP62, USP63, USP64, USP65, USP66, USP67, USP68, USP69, USP70, USP71, USP72, USP73, USP74, USP75, USP76, USP77, USP78, USP79, USP80, USP81, USP82, USP83, USP84, USP85, USP86, USP87, USP88, USP89, USP90, USP91, USP92, Exemplary deubiquitinases for use in the present disclosure include, but are not limited to, SP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, USP46, BAP1, UCHL1, UCHL3, UCHL5, ATXN3, ATXN3L, OTUB1, OTUB2, MINDY1, MINDY2, MINDY3, MINDY4, and ZUP1. Exemplary deubiquitinases for use in the present disclosure are also disclosed in Komander, D. et al. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10, 550-563 (2009), the entire contents of which are incorporated herein by reference.

[0195] In some embodiments, the deubiquitinating enzyme is USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP39L10, USP39L11, USP39L12, USP39L13, USP39L14, USP39L15, USP39L16, USP39L17, USP39L18, USP39L19, USP39L19, USP39L20, USP39L21, USP39L22, USP39L23, USP39L24, USP39L25, USP39L30, USP39L41, USP39L52, USP39L6, USP39L73, USP39L84, USP39L95, USP39L10, USP39L11, USP39L12, USP39L13, USP39L14, USP39L15, USP39L16, USP39L17, USP39L18, USP 9, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, and USP46.

[0196] In some embodiments, the deubiquitinase is BAP1, UCHL1, UCHL3, or UCHL5. In some embodiments, the deubiquitinase is ATXN3 or ATXN3L. In some embodiments, the deubiquitinase is OTUB1 or OTUB2. In some embodiments, the deubiquitinase is MINDY1, MINDY2, MINDY3, or MINDY4. In some embodiments, the deubiquitinase is ZUP1. In some embodiments, the deubiquitinase is Jab1 / Mov34 / Mpr1 Pad1 N-terminal+(MPN+) (JAMM) domain protease.

[0197] In some embodiments, the deubiquitinase is a deubiquitinase listed in Table 1. In some embodiments, the amino acid sequence of the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of a deubiquitinase in Table 1. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the catalytic domain of a deubiquitinase in Table 1. In some embodiments, the effector domain comprises a functional fragment of a deubiquitinase in Table 1. In some embodiments, the effector domain of a deubiquitinase comprises a functional variant of a deubiquitinase in Table 1. In some embodiments, the catalytic domain comprises a functional fragment of the catalytic domain of a deubiquitinase in Table 1. In some embodiments, the catalytic domain comprises a functional variant of the catalytic domain of a deubiquitinase in Table 1.

[0198] In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112. In some embodiments, the deubiquitinase consists of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112.

[0199] In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:2. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 3. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 4. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 5. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 6. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:7.In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 8. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:9. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:10. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 11. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 12. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 13. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 14. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 15. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 16. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:17.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 18. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 19. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:20. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 22. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 23. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 24. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 25. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 26. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:27.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 28. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 29. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:30. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 31. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 32. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 33. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 34. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 35. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 36. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:37.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 38. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:40. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 42. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 43. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 44. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 45. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 46. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:47.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 48. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 49. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:50. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 51. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 52. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 53. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 54. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 55. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 56. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:57.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:60. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 61. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 62. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 63. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 64. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 65. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 66. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:67.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 68. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 69. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:70. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 71. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 72. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 73. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 74. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 75. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 76. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:77.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 79. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:80. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 81. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 82. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 83. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 84. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 85. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:86. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:87.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 88. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:89. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:90. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 91. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 92. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 93. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:94. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 95. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:96. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:97.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 98. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:99. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:100. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 101. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 102. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 103. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 104. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 105. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 106. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:107.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 108. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:110. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 111. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 112.

[0200] In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of any one of SEQ ID NOs: 1-112. In some embodiments, the amino acid sequence of the effector domain consists of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of any one of SEQ ID NOs: 1-112.

[0201] In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 1. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:2. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 3. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 4. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 5. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 6.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 7. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:8. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 9. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 10. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 11. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 12. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 13. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 14. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 15. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 16.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 17. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 18. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 19. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:20. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 21. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 22. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 23. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 24. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 25. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 26.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 27. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 28. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 29. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 30. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 31. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 32. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 33. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 34. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 35. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 36.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 37. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 38. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 39. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 40. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 41. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 42. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 43. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 44. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 45. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 46.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 47. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 48. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 49. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:50. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 51. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 52. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 53. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 54. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 55. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 56.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 57. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 58. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 59. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 60. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 61. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 62. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 63. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 64. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 65. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 66.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 67. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 68. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 69. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 70. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 71. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 72. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 73. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 74. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 75. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 76.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 77. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 78. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 79. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:80. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 81. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 82. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 83. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 84. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 85. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 86.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 87. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:88. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 89. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:90. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 91. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 92. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 93. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:94. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 95. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 96.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 97. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:98. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 99. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 100. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 101. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 102. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 103. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 104. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 105. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 106.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 107. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 108. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 109. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 110. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 111. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 112.

[0202] In some embodiments, the catalytic domain is derived from a deubiquitinase that comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 1-112. In some embodiments, the catalytic domain is derived from a deubiquitinase that consists of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 1-112.

[0203] In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:2. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 3. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 4. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 5. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 6.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 7. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:8. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 9. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 13. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 14. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 15. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 16.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 17. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 19. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:20. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 21. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 22. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 23. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 24. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 25. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 26.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 27. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 28. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 29. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 30. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 31. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 32. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 33. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 34. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 35. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 36.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 38. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 39. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 40. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 41. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 42. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 43. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 44. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 45. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 46.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 47. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 48. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 49. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:50. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 51. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 52. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 53. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 54. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 55. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 56.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 57. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 58. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 59. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 60. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 61. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 62. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 63. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 64. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 66.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 67. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 68. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 69. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 70. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 71. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 72. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 73. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 74. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 75. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 76.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 77. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 78. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 79. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 80. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 81. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 82. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 83. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 84. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 85. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 86.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 87. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 88. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 89. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:90. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 91. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 92. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 93. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 94. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 95. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 96.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 97. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:98. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 99. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 100. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 101. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 102. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 103. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 104. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 105. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 106.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 107. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 108. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 109. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 110. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 111. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112.

[0204] In some embodiments, the catalytic domain comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 113-220 or 293. In some embodiments, the catalytic domain consists of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 113-220.

[0205] In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 113. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 114. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 115. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 116. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 117. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:119.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:120. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 121. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 122. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 123. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 124. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 125. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 126. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 127.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 128. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 129. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:130. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 131. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 132. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 133. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 134. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 135. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 136. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 137.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 138. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 139. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:140. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 141. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 142. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 143. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 144. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 145. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 146. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 147.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 148. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 149. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 150. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 151. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 152. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 153. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 154. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 155. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 156. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 157.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 158. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 159. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:160. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 161. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 162. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 163. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 164. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 165. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 166. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 167.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 168. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 169. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 170. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 171. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 172. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 173. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 174. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 175. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 177.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 178. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 179. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 180. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 181. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 182. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 183. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 184. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 185. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 186. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 187.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 188. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 189. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 190. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 191. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 192. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 193. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 194. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 195. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 196. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:197.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 198. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 199. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:200. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 201. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 202. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 203. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 204. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 205. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 206. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:207.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 208. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 209. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:210. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 211. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 213. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 214. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 215. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 216. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:217.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 219. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:220. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:293.

[0206] Table 1 below lists exemplary human deubiquitinating enzymes and the amino acid sequences of exemplary catalytic domains of exemplary human deubiquitinating enzymes. The catalytic domains are exemplary. One of skill in the art could readily determine the amino acid sequence (e.g., catalytic domain) of a human deubiquitinating enzyme sufficient to mediate deubiquitination. Any human deubiquitinating enzyme (functional fragment or variant thereof) can be used to derive a catalytic domain for use in the fusion proteins described herein.

[0207] [Table 1-1]

[0208] [Table 1-2]

[0209]

Table 1-3

[0210]

Table 1-4

[0211]

Table 1-5

[0212]

Table 1-6

[0213]

Table 1-7

[0214]

Table 1-8

[0215]

Table 1-9

[0216]

Table 1-10

[0217]

Table 1-11

[0218]

Table 1-12

[0219]

Table 1-13

[0220]

Table 1-14

[0221]

Table 1-15

[0222]

Table 1-16

[0223]

Table 1-17

[0224]

Table 1-18

[0225]

Table 1-19

[0226]

Table 1-20

[0227]

Table 1-21

[0228]

Table 1-22

[0229]

Table 1-23

[0230]

Table 1-24

[0231]

Table 1-25

[0232]

Table 1-26

[0233]

Table 1-27

[0234]

Table 1-28

[0235]

Table 1-29

[0236]

Table 1-30

[0237]

Table 1-31

[0238]

Table 1-32

[0239]

Table 1-33

[0240]

Table 1-34

[0241]

Table 1-35

[0242]

Table 1-36

[0243]

Table 1-37

[0244]

Table 1-38

[0245]

Table 1-39

[0246]

Table 1-40

[0247]

Table 1-41

[0248]

Table 1-42

[0249]

Table 1-43

[0250]

Table 1-44

[0251]

Table 1-45

[0252]

Table 1-46

[0253]

Table 1-47

[0254]

Table 1-48

[0255]

Table 1-49

[0256]

Table 1-50

[0257]

Table 1-51

[0258]

Table 1-52

[0259]

Table 1-53

[0260]

Table 1-54

[0261]

Table 1-55

[0262]

Table 1-56

[0263]

Table 1-57

[0264]

Table 1-58

[0265]

Table 1-59

[0266]

Table 1-60

[0267]

Table 1-61

[0268]

Table 1-62

[0269]

Table 1-63

[0270]

Table 1-64

[0271]

Table 1-65

[0272]

Table 1-66

[0273]

Table 1-67

[0274]

Table 1-68

[0275]

Table 1-69

[0276]

Table 1-70

[0277]

Table 1-71

[0278]

Table 1-72

[0279] 5.3.2 Targeting Domains In some embodiments, the targeting domain comprises a targeting moiety that specifically binds to a target membrane protein. In some embodiments, the targeting moiety comprises an antibody (or an antigen-binding fragment thereof). In some embodiments, the antibody is a full-length antibody, a single-chain variable fragment (scFv), (scFv)2, scFv-Fc, Fab, Fab', (Fab')2, F(v), a single-domain antibody, a single-chain antibody, a VHH, or a (VHH)2. In some embodiments, the targeting moiety comprises a VHH. In some embodiments, the targeting moiety comprises a (VHH)2.

[0280] In some embodiments, the targeting moiety specifically binds to a wild-type target membrane protein. In some embodiments, the targeting moiety specifically binds to a wild-type target membrane protein but not to a variant of the target membrane protein associated with a genetic disease. In some embodiments, the targeting moiety specifically binds to a naturally occurring variant of the target membrane protein. In some embodiments, the targeting moiety specifically binds to a naturally occurring variant of the target membrane protein associated with a genetic disease (e.g., a genetic disease described herein). In some embodiments, the targeting moiety specifically binds to a naturally occurring variant of the target membrane protein that is the cause of a genetic disease (e.g., a genetic disease described herein). In some embodiments, the targeting moiety specifically binds to a naturally occurring variant of the target membrane protein that is a loss-of-function variant. In some embodiments, the targeting moiety specifically binds to a naturally occurring variant of the target membrane protein that is a loss-of-function variant associated with a genetic disease (e.g., a genetic disease described herein). In some embodiments, the targeting moiety specifically binds to a naturally occurring variant of the target membrane protein that is a loss-of-function variant that causes a genetic disease (e.g., a genetic disease described herein).

[0281] 5.3.2.1 Exemplary Target Membrane Proteins In some embodiments, the targeting moiety specifically binds to a target membrane protein (e.g., a membrane protein described herein). Exemplary target membrane proteins include ionotropic glutamate receptor NMDA 2B (GRIN2B), cystic fibrosis transmembrane conductance regulator (CFTR), sodium channel protein type 1 subunit alpha (SCN1A), copper-transporting ATPase 2 (ATP7B), potassium voltage-gated channel subfamily KQT member 2 (KCNQ2), sodium channel protein type 2 subunit alpha (SCN2A), voltage-gated P / Q-type calcium channel subunit alpha-1A (CACNA1A), solute carrier family 2, facilitative glucose transporter member 1 (SLC2A1), sodium channel protein type 8 subunit alpha (SCN8A), proline-rich transmembrane protein 2 (PRRT2), ionotropic glutamate receptor NMDA 2A (GRIN2A), sodium and chloride-dependent GABA transporter 1 (SLC6A1), usherin (USH2A), sodium / potassium transporting ATPase subunit alpha-2 (ATP1A2), sodium / potassium transporting ATPase subunit alpha-3 (ATP1A3), sodium channel protein type 9 subunit alpha (SCN9A), protocadherin-19 (PCDH19), gamma-aminobutyric acid receptor subunit beta-3 (GA These include, but are not limited to, BRB3), tuberin (TSC2), hamartin (TSC1), potassium voltage-gated channel subfamily KQT member 3 (KCNQ3), dystrophin (DMD), rhodopsin (RHO), Jagged 1 protein (JAG1), inositol 1,4,5-trisphosphate receptor type 1 (ITPR1), sugar transporter SWEET1 (SLC50A1), transmembrane protein 258 (TMEM258), and follicle-stimulating hormone receptor (FSHR).

[0282] In some embodiments, the target membrane protein is GRIN2B. In some embodiments, the target membrane protein is CFTR. In some embodiments, the target membrane protein is SCN1A. In some embodiments, the target membrane protein is ATP7B. In some embodiments, the target membrane protein is KCNQ2. In some embodiments, the target membrane protein is SCN2A. In some embodiments, the target membrane protein is CACNA1A. In some embodiments, the target membrane protein is SLC2A1. In some embodiments, the target membrane protein is SCN8A. In some embodiments, the target membrane protein is PRRT2. In some embodiments, the target membrane protein is GRIN2A. In some embodiments, the target membrane protein is SLC6A1. In some embodiments, the target membrane protein is USH2A. In some embodiments, the target membrane protein is ATP1A2. In some embodiments, the target membrane protein is ATP1A3. In some embodiments, the target membrane protein is SCN9A. In some embodiments, the target membrane protein is PCDH19. In some embodiments, the target membrane protein is GABRB3. In some embodiments, the target membrane protein is TSC2. In some embodiments, the target membrane protein is TSC1. In some embodiments, the target membrane protein is KCNQ3. In some embodiments, the target membrane protein is DMD. In some embodiments, the target membrane protein is RHO. In some embodiments, the target membrane protein is JAG1. In some embodiments, the target membrane protein is ITPR1. In some embodiments, the target membrane protein is sugar transporter SWEET1 (SLC50A1). In some embodiments, the target membrane protein is transmembrane protein 258 (TMEM258). In some embodiments, the target membrane protein is follicle-stimulating hormone receptor (FSHR).

[0283] In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 221-245. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 221. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 222. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 223. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 224. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 225. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 226. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 227. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 228.In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 229. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 230. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 240. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 241. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 242. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 243. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 244. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 245. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 294. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 295. In some embodiments, the target membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 296.

[0284] Table 2 below provides the wild-type amino acid sequences of exemplary proteins to target for deubiquitination using the fusion proteins described herein.

[0285] [Table 2-1]

[0286] [Table 2-2]

[0287] [Table 2-3]

[0288] [Table 2-4]

[0289] [Table 2-5]

[0290] [Table 2-6]

[0291]

Table 2-7

[0292]

Table 2-8

[0293]

Table 2-9

[0294]

Table 2-10

[0295]

Table 2-11

[0296]

Table 2-12

[0297]

Table 2-13

[0298]

Table 2-14

[0299]

Table 2-15

[0300]

Table 2-16

[0301] [Table 2-17]

[0302] [Table 2-18]

[0303] [Table 2-19]

[0304] [Table 2-20]

[0305] [Table 2-21]

[0306] [Table 2-22]

[0307] 5.3.3 Orientation and Linkers In some embodiments, the effector domain is at the N-terminus of the targeting domain in the fusion protein. In some embodiments, the targeting domain is at the N-terminus of the effector domain in the fusion protein. In some embodiments, the effector domain is operably connected (directly or indirectly) to the C-terminus of the targeting domain. In some embodiments, the effector domain is operably connected (directly or indirectly) to the N-terminus of the targeting domain. In some embodiments, the effector domain is operably connected directly to the C-terminus of the targeting domain. In some embodiments, the effector domain is operably connected directly to the N-terminus of the targeting domain.

[0308] In some embodiments, the effector domain is indirectly operably connected to the C-terminus of the targeting domain.In some embodiments, the effector domain is indirectly operably connected to the N-terminus of the targeting domain.For example, one or more amino acid sequences comprising a linker or encoding one or more polypeptides can be located between the effector moiety and the targeting moiety.In some embodiments, the effector domain is indirectly operably connected to the C-terminus of the targeting domain via a peptide linker.In some embodiments, the effector domain is indirectly operably connected to the N-terminus of the targeting domain via a peptide linker.

[0309] Each component of the fusion proteins described herein may be directly linked to the other or indirectly linked to the other via a peptide linker. Any suitable peptide linker known in the art that enables the effector domain and targeting domain to bind to their respective antigens can be used. In some embodiments, the linker is one or any combination of a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, or a non-helical linker. In some embodiments, the linker is a peptide linker. In some embodiments, the linker is a peptide linker containing glycine or serine, or both glycine and serine amino acid residues. In some embodiments, the peptide linker contains approximately 1-20, 1-15, 1-10, 1-5, 5-20, 5-15, 5-10, or 15-20 amino acids. In some embodiments, the peptide linker comprises 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, or 5-10 amino acids, or about 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, or 5-10 amino acids. In some embodiments, the linker is a peptide linker consisting of glycine or serine, or both glycine and serine amino acid residues. In some embodiments, the peptide linker consists of 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, or 5-10 amino acids, or about 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, or 5-10 amino acids.In some embodiments, the peptide linker comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid residues. In some embodiments, the linker is at least 11 amino acids in length. In some embodiments, the linker is at least 15 amino acids in length. In some embodiments, the linker is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid residues in length.

[0310] In some embodiments, the linker is a glycine / serine linker, e.g., a peptide linker consisting essentially of the amino acids glycine and serine, hi some embodiments, the linker is a glycine / serine / proline linker, e.g., a peptide linker consisting essentially of the amino acids glycine, serine, and proline.

[0311] In some embodiments, the amino acid sequence of the linker comprises the amino acid sequence of any one of SEQ ID NOs: 297-424, or the amino acid sequence of any one of SEQ ID NOs: 297-424 with one, two, or three amino acid modifications (e.g., substitutions, deletions, or additions). In some embodiments, the amino acid sequence of the linker consists of the amino acid sequence of any one of SEQ ID NOs: 297-424, or the amino acid sequence of any one of SEQ ID NOs: 297-424 with one, two, or three amino acid modifications (e.g., substitutions, deletions, or additions).

[0312] In some embodiments, the amino acid sequence of the linker comprises the amino acid sequence of any one of SEQ ID NOs: 297-306, or the amino acid sequence of any one of SEQ ID NOs: 297-288 with one, two, or three amino acid modifications (e.g., substitutions, deletions, or additions). In some embodiments, the amino acid sequence of the linker consists of the amino acid sequence of any one of SEQ ID NOs: 297-306, or the amino acid sequence of any one of SEQ ID NOs: 297-306 with one, two, or three amino acid modifications (e.g., substitutions, deletions, or additions).

[0313] The amino acid sequences of exemplary linkers for use in any one or more of the fusion proteins described herein are provided in Table 3 below.

[0314] [Table 3-1]

[0315] [Table 3-2]

[0316] [Table 3-3]

[0317] 5.3.3.1 Conditional constructs Also described herein are constructs comprising a targeting domain (e.g., VHH, (VHH)2) linked to an effector domain (e.g., an effector domain comprising a catalytic domain of a deubiquitinase, or an effector domain comprising a deubiquitinase). In some embodiments, the linkage between the targeting domain and the effector domain is mediated by binding between a first agent (e.g., a small molecule, protein, or peptide) associated with the targeting domain and a second agent (e.g., a small molecule, protein, or peptide) associated with the effector domain. For example, in one embodiment, the targeting domain may be linked to a first agent that specifically binds to the second agent associated with the effector domain. In some embodiments, the specific binding of the first agent to the second agent is mediated by the addition of a third agent (e.g., a small molecule).

[0318] For example, conditional constructs including KBP / FRB-based dimerization switches, such as those described in, for example, U.S. Patent Application Publication No. 2017 / 0081411 (the entire contents of which are incorporated herein by reference), can be utilized herein. FKBP12 (FKBP or FK506-binding protein) is an abundant cytoplasmic protein that serves as the primary intracellular target for the natural product immunosuppressant, rapamycin. Rapamycin binds to FKBP and the large PI3K homolog FRAP (RAFT, mTOR), thereby acting to dimerize these molecules. In some embodiments, FKBP / FRAP-based switches, also referred to herein as FKBP / FRB-based switches, can utilize heterodimerization molecules, such as rapamycin or rapamycin analogs. FRB is a 93-amino acid portion of FRAP sufficient to bind to the FKBP-rapamycin complex (Chen, J., Zheng, XF, Brown, EJ & Schreiber, SL (1995) Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA 92: 4947-51, the entire contents of which are incorporated herein by reference). For example, the targeting domain can bind to FKBP, and the effector domain can bind to FRB. Thus, the link between the targeting domain and the effector domain is mediated by rapamycin and occurs only in the presence of rapamycin.

[0319] Exemplary conditional activation systems that can be used herein include those described in U.S. Patent Application Publication No. 2017 / 0081411; Lajoie MJ, et al. Designed protein logic to target cells with precise combinations of surface antigens. Science. 2020 Sep 25;369(6511):1637-1643. doi: 10.1126 / science.aba6527. Epub 2020 Aug 20. PMID: 32820060; Farrants H, et al. Chemogenetic Control of Nanobodies. Nat Methods. 2020 Mar;17(3):279-282. doi: 10.1038 / s41592-020-0746-7. Epub 2020 Feb 17. PMID: 32066961; and those described in U.S. Patent Application Publication No. 2017 / 0081411.

[0320] 5.3.4 Exemplary Fusion Proteins Exemplary fusion proteins of the present disclosure include, but are not limited to, the following: In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a cysteine ​​protease deubiquitinase, or a functional fragment or variant thereof; and a targeting domain comprising a targeting moiety that specifically binds to a membrane protein, wherein the membrane protein is GRIN2B, CFTR, SCN1A, ATP7B, KCNQ2, SCN2A, CACNA1A, SLC2A1, SCN8A, PRRT2, GRIN2A, SLC6A1, USH2A, ATP1A2, ATP1A3, SCN9A, PCDH19, GABRB3, TSC2, TSC1, KCNQ3, DMD, RHO, JAG1, ITPR1, SLC50A1, TMEM258, or FSHR.

[0321] In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a metalloprotease deubiquitinase, or a functional fragment or functional variant thereof; and a targeting domain comprising a targeting moiety that specifically binds to a membrane protein, wherein the membrane protein is GRIN2B, CFTR, SCN1A, ATP7B, KCNQ2, SCN2A, CACNA1A, SLC2A1, SCN8A, PRRT2, GRIN2A, SLC6A1, USH2A, ATP1A2, ATP1A3, SCN9A, PCDH19, GABRB3, TSC2, TSC1, KCNQ3, DMD, RHO, JAG1, ITPR1, SLC50A1, TMEM258, or FSHR.

[0322] In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the deubiquitinase is a ubiquitin-specific protease (USP), a ubiquitin C-terminal hydrolase (UCH), a Machado-Josephine domain protease (MJD), an ovarian tumor protease (OTU), a MINDY protease, or a ZUFSP protease; and a target protein that specifically binds to a membrane protein. a targeting domain comprising a targeting moiety, wherein the membrane protein is GRIN2B, CFTR, SCN1A, ATP7B, KCNQ2, SCN2A, CACNA1A, SLC2A1, SCN8A, PRRT2, GRIN2A, SLC6A1, USH2A, ATP1A2, ATP1A3, SCN9A, PCDH19, GABRB3, TSC2, TSC1, KCNQ3, DMD, RHO, JAG1, ITPR1, SLC50A1, TMEM258, or FSHR1.

[0323] In one embodiment, the fusion protein is an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the deubiquitinase is selected from the group consisting of USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP 17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP19, USP20, USP21, USP22, USP23, USP24, USP25, USP 26, USP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, US an effector domain selected from the group consisting of P42, USP43, USP44, USP45, USP46, BAP1, UCHL1, UCHL3, UCHL5, ATXN3, ATXN3L, OTUB1, OTUB2, MINDY1, MINDY2, MINDY3, MINDY4, or ZUP1; and a targeting domain comprising a targeting moiety that specifically binds to a membrane protein, wherein the membrane protein is a GR and a targeting domain that is IN2B, CFTR, SCN1A, ATP7B, KCNQ2, SCN2A, CACNA1A, SLC2A1, SCN8A, PRRT2, GRIN2A, SLC6A1, USH2A, ATP1A2, ATP1A3, SCN9A, PCDH19, GABRB3, TSC2, TSC1, KCNQ3, DMD, RHO, JAG1, ITPR1, SLC50A1, TMEM258, or FSHR.

[0324] In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, where the deubiquitinase is listed in Table 1; and a targeting domain comprising a targeting moiety that specifically binds to a membrane protein, where the membrane protein is GRIN2B, CFTR, SCN1A, ATP7B, KCNQ2, SCN2A, CACNA1A, SLC2A1, SCN8A, PRRT2, GRIN2A, SLC6A1, USH2A, ATP1A2, ATP1A3, SCN9A, PCDH19, GABRB3, TSC2, TSC1, KCNQ3, DMD, RHO, JAG1, ITPR1, SLC50A1, TMEM258, or FSHR.

[0325] In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the catalytic domain is described in Table 1; and a targeting domain comprising a targeting moiety that specifically binds to a membrane protein, wherein the membrane protein is GRIN2B, CFTR, SCN1A, ATP7B, KCNQ2, SCN2A, CACNA1A, SLC2A1, SCN8A, PRRT2, GRIN2A, SLC6A1, USH2A, ATP1A2, ATP1A3, SCN9A, PCDH19, GABRB3, TSC2, TSC1, KCNQ3, DMD, RHO, JAG1, ITPR1, SLC50A1, TMEM258, or FSHR.

[0326] In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112; and an effector domain that specifically binds to a membrane protein. and a targeting domain comprising a targeting moiety associated with the targeting domain, wherein the membrane protein is GRIN2B, CFTR, SCN1A, ATP7B, KCNQ2, SCN2A, CACNA1A, SLC2A1, SCN8A, PRRT2, GRIN2A, SLC6A1, USH2A, ATP1A2, ATP1A3, SCN9A, PCDH19, GABRB3, TSC2, TSC1, KCNQ3, DMD, RHO, JAG1, ITPR1, SLC50A1, TMEM258, or FSHR.

[0327] In one embodiment, the fusion protein comprises an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the catalytic domain comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 113-220 or 293; and an effector domain specific for a membrane protein. and a targeting domain comprising a targeting moiety that binds to the membrane protein, wherein the membrane protein is GRIN2B, CFTR, SCN1A, ATP7B, KCNQ2, SCN2A, CACNA1A, SLC2A1, SCN8A, PRRT2, GRIN2A, SLC6A1, USH2A, ATP1A2, ATP1A3, SCN9A, PCDH19, GABRB3, TSC2, TSC1, KCNQ3, DMD, RHO, JAG1, ITPR1, SLC50A1, TMEM258, or FSHR.

[0328] In one embodiment, the fusion protein is an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the deubiquitinase is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or a combination of any one of SEQ ID NOs: 1-112. an effector domain comprising an amino acid sequence that is 100% identical; and a targeting domain comprising a targeting moiety that specifically binds to a membrane protein, wherein the membrane protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 221-245 or 294-296.

[0329] In one embodiment, the fusion protein is an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the catalytic domain is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 161%, 162%, 163%, 164%, 165%, 166%, 167%, 168%, 169%, 170%, 171%, 172%, 173%, 174%, 175%, 176%, 177%, or 100% identical amino acid sequence to any one of SEQ ID NOs: 221-245 or 294-296; and a targeting domain comprising a targeting moiety that specifically binds to a membrane protein, wherein the membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 221-245 or 294-296.

[0330] 5.3.4.1 Further Exemplary Embodiments Further exemplary embodiments of the fusion proteins described herein, which should not be construed as limiting, are provided below.

[0331] Embodiment 1. (a) A fusion protein comprising: an effector moiety comprising a functional fragment of a human deubiquitinase capable of mediating deubiquitination, wherein the human deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 1 to 112; and a targeting moiety comprising a VHH, (VHH)2, or scFv that specifically binds to a membrane protein.

[0332] Embodiment 2. A fusion protein comprising: an effector portion comprising a functional fragment of a human deubiquitinase capable of mediating deubiquitination, the functional fragment comprising an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 113 to 220 or 293; and a targeting portion comprising a VHH, (VHH)2, or scFv that specifically binds to a membrane protein.

[0333] Embodiment 3. A fusion protein comprising an effector moiety comprising a functional fragment of a human deubiquitinase capable of mediating deubiquitination, the functional fragment comprising an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 293, and a targeting moiety comprising a VHH, (VHH)2, or scFv that specifically binds to a membrane protein.

[0334] Embodiment 4. 4. The fusion protein of any one of embodiments 1 to 3, wherein the targeting moiety is a VHH or (VHH)2.

[0335] Embodiment 5.5. The fusion protein of any one of embodiments 1 to 4, wherein the membrane protein is GRIN2B, CFTR, SCN1A, ATP7B, KCNQ2, SCN2A, CACNA1A, SLC2A1, SCN8A, PRRT2, GRIN2A, SLC6A1, USH2A, ATP1A2, ATP1A3, SCN9A, PCDH19, GABRB3, TSC2, TSC1, KCNQ3, DMD, RHO, JAG1, ITPR1, SLC50A1, TMEM258, or FSHR.

[0336] Embodiment 6. 4. The fusion protein of any one of embodiments 1 to 3, wherein the membrane protein is SCN1A, GRIN2B, SLC50A1, TMEM258, or FSHR.

[0337] 5.3.5 Methods for Producing Fusion Proteins The fusion proteins described herein can be produced by any conventional technique known in the art, such as recombinant technology or chemical synthesis (e.g., solid-phase peptide synthesis). In some embodiments, the fusion protein is produced by recombinant expression in a cell (e.g., a eukaryotic cell, e.g., a mammalian cell). Briefly, the fusion protein can be produced by synthesizing DNA encoding the fusion protein and cloning the DNA into any appropriate expression vector. Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of preference. The gene can be placed under the control of a promoter, a ribosome binding site (for bacterial expression), and optionally an operator and / or one or more enhancer elements, such that the DNA sequence encoding the fusion protein is transcribed into RNA in a host cell transformed with a vector containing the expression construct. The coding sequence may or may not contain a signal peptide or leader sequence. A heterologous leader sequence can be added to the coding sequence to cause secretion of the expressed polypeptide from the host organism. Other regulatory sequences that allow for regulation of the expression of the protein sequence relative to the growth of the host cell may also be desirable. Such regulatory sequences are known to those skilled in the art, and examples include those that turn on and off gene expression in response to chemical or physical stimuli, including the presence of regulatory compounds.Other types of regulatory elements can also be present in vectors, such as enhancer sequences.Regulatory sequences and other regulatory sequences may be ligated to coding sequences before being inserted into vectors, such as the above-mentioned cloning vectors.Alternatively, coding sequences can be directly cloned into expression vectors that already contain regulatory sequences and suitable restriction sites.

[0338] The expression vector can then be used to transform an appropriate host cell. Several mammalian cell lines are known in the art, including immortalized cell lines available from the American Type Culture Collection (ATCC), such as, but not limited to, Chinese hamster ovary (CHO) cells, CHO-suspension cells (CHO-S), HeLa cells, HEK293, baby hamster kidney (BHK) cells, monkey kidney cells (COS), VERO, HepG2, Madin-Darby bovine kidney (MDBK) cells, NOS, U2OS, A549, HT1080, CAD, P19, NIH3T3, L929, N2a, MCF-7, Y79, SO-Rb50, DUKX-X11, and J558L.

[0339] Depending on the selected expression system and host, the fusion protein is produced by growing host cells transformed with the expression vector under conditions in which the fusion protein is expressed. The fusion protein is then isolated and purified from the host cells. If the expression system secretes the fusion protein into the growth medium, the fusion protein can be purified directly from the medium. If the fusion protein is not secreted, it is isolated from cell lysates. The selection of appropriate growth conditions and recovery methods is within the skill of those skilled in the art. After purification, the amino acid sequence of the fusion protein can be determined by repeated cycles of Edman degradation followed by amino acid analysis by HPLC. Other amino acid sequencing methods are also known in the art. After purification, the functionality of the fusion protein can be evaluated, for example, using a bifunctional ELISA, as described herein.

[0340] As described above, the functionality of the fusion protein can be tested by any method known in the art. Each functionality can be measured in a separate assay. For example, the binding of the targeting domain to the target protein can be measured using an enzyme-linked immunosorbent assay (ELISA). The catalytic activity of the effector domain can be measured using any standard deubiquitinase activity assay known in the art, such as the BioVision Deubiquitinase Activity Assay Kit (Fluorometric) Catalog No. K485-100, according to the manufacturer's instructions. The deubiquitinase activity of the fusion proteins described herein can be measured, for example, by using a fluorescent deubiquitinase substrate to detect deubiquitinase activity when the fluorescent substrate is cleaved. Deubiquitinase activity can also be measured using the materials and methods shown in the Examples provided herein.

[0341] 5.4 Nucleic Acids, Host Cells, Vectors, and Viral Particles In one aspect, the present specification provides a nucleic acid molecule encoding the fusion protein described herein.In some embodiments, the nucleic acid molecule is a DNA molecule.In some embodiments, the nucleic acid molecule is an RNA molecule.In some embodiments, the nucleic acid molecule contains at least one modified nucleic acid (e.g., one that increases the stability of the nucleic acid molecule), such as phosphorothioate, N6-methyladenosine (m6A), N6,2'-O-dimethyladenosine (m6Am), 8-oxo-7,8-dihydroguanosine (8-oxoG), pseudouridine (Ψ), 5-methylcytidine (m5C), and N4-acetylcytidine (ac4C).

[0342] In one aspect, provided herein is a host cell (or population of host cells) comprising a nucleic acid encoding a fusion protein described herein. In some embodiments, the nucleic acid is integrated into the genome of the host cell. In some embodiments, the nucleic acid is not integrated into the genome of the host cell. In some embodiments, the nucleic acid is present in an episome of the cell. In some embodiments, the host cell is a human cell. In some embodiments, the host cell is a mammalian cell. In some embodiments, the host cell is a mouse, rat, hamster, guinea pig, cat, dog, or human cell. In some embodiments, the host cell is modified in vitro, ex vivo, or in vivo.

[0343] Nucleic acid can be introduced into host cell by any suitable method known in the art (for example, as described herein).For example, viral delivery system (for example, retrovirus, adenovirus, adeno-associated virus, herpesvirus, lentivirus, poxvirus, vaccinia virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, Epstein-Barr virus, influenza virus, retrovirus, myxoma virus, Maraba virus, rhabdovirus or coxsackie virus delivery system) can be used to deliver the nucleic acid (for example, DNA or RNA molecule) encoding fusion protein for expression in host cell.In some embodiments, the nucleic acid encoding fusion protein is present in episome in host cell.In some embodiments, the nucleic acid encoding fusion protein is integrated into the genome of host cell.In some embodiments, the virus is capable of replication.In some embodiments, the virus is replication-defective.

[0344] In some embodiments, nucleic acids (DNA or RNA) are delivered to host cells using non-viral vectors (e.g., plasmids) encoding fusion proteins. In some embodiments, the nucleic acids encoding fusion proteins are present in episomes within host cells. In some embodiments, the nucleic acids encoding fusion proteins are integrated into the genome of host cells. Exemplary non-viral transfection methods known in the art include, but are not limited to, direct delivery of DNA by ex vivo transfection, injection (e.g., microinjection), electroporation, liposome-mediated transfection, receptor-mediated transfection, particle bombardment, or agitation with silicon carbide fibers. By applying such techniques, nucleic acids encoding the fusion proteins described herein may be stably or transiently transfected into these cells to express the encoded fusion proteins.

[0345] In one aspect, the present specification provides a vector comprising the nucleic acid encoding the fusion protein described herein (for example, the nucleic acid described herein).In some embodiments, the vector is a viral vector.Exemplary viral vectors include but are not limited to retroviral vectors, adenoviral vectors, adeno-associated viral vectors, herpesvirus vectors, lentivirus vectors, poxvirus vectors, vaccinia virus vectors, vesicular stomatitis virus vectors, poliovirus vectors, Newcastle disease virus vectors, Epstein-Barr virus vectors, influenza virus vectors, reovirus vectors, myxoma virus vectors, Maraba virus vectors, rhabdovirus vectors and coxsackievirus vectors.In some embodiments, the vector is a non-viral vector.In some embodiments, the non-viral vector is a plasmid.

[0346] In one aspect, provided herein is a viral particle (or a population of viral particles) comprising a nucleic acid (for example, a nucleic acid described herein) encoding the fusion protein described herein.In some embodiments, the viral particle is an RNA virus.In some embodiments, the viral particle is a DNA virus.In some embodiments, the viral particle comprises a double-stranded genome.In some embodiments, the viral particle comprises a single-stranded genome.Exemplary viral particles include, but are not limited to, retrovirus, adenovirus, adeno-associated virus, herpesvirus, lentivirus, poxvirus, vaccinia virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, Epstein-Barr virus, influenza virus, reovirus, myxoma virus, Maraba virus, rhabdovirus, or coxsackie virus.

[0347] 5.5 Pharmaceutical Compositions In one aspect, provided herein is a pharmaceutical composition comprising: 1) a fusion protein described herein, a nucleic acid encoding a fusion protein described herein, a vector comprising a nucleic acid encoding a fusion protein described herein, or a viral particle comprising a nucleic acid encoding a fusion protein described herein; and 2) at least one pharmaceutically acceptable carrier, excipient, stabilizer, buffer, diluent, surfactant, preservative, and / or adjuvant (see, e.g., Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, PA). One skilled in the art can select an appropriate excipient for inclusion in the pharmaceutical composition. For example, the formulation of the pharmaceutical composition may vary based on the route of administration (e.g., intravenous, subcutaneous, etc.) and / or the active molecule contained in the pharmaceutical composition (e.g., a viral particle, a non-viral vector, a nucleic acid not contained in a vector).

[0348] Acceptable carriers, excipients, or stabilizers are preferably nontoxic to recipients at the dosages and concentrations employed, and may include buffers such as phosphates, citrates, or other organic acids; antioxidants, including ascorbic acid or methionine; preservatives (e.g., octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl alcohol, or benzyl alcohol; alkyl parabens, such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; or m-cresol); low molecular weight (less than about 10 residues) polypeptides; These include proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, or other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN®, PLURONICS®, or polyethylene glycol (PEG).

[0349] In one embodiment, the present disclosure provides a pharmaceutical composition comprising the fusion protein described herein for use as a medicament.In another embodiment, the present disclosure provides a pharmaceutical composition for use in a method for treating cancer.In some embodiments, the pharmaceutical composition comprises the fusion protein disclosed herein and optionally one or more additional prophylactic or therapeutic agents in a pharmaceutically acceptable carrier.

[0350] The pharmaceutical composition may be formulated for any route of administration to a subject. Specific examples of routes of administration include parenteral administration (e.g., intravenous, subcutaneous, intramuscular). In some embodiments, the pharmaceutical composition is formulated for intravenous administration. In some embodiments, the pharmaceutical composition is formulated for subcutaneous administration. Injections can be prepared in conventional forms, either as solutions or suspensions. Injections may contain one or more excipients. Exemplary excipients include, for example, water, saline, dextrose, glycerol, or ethanol. In addition, if desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, or other agents, such as, for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, or cyclodextrins.

[0351] In some embodiments, the pharmaceutical composition is formulated for intravenous administration. Suitable carriers for intravenous administration include saline or phosphate buffered saline (PBS), or solutions containing thickening or solubilizing agents such as glucose, polyethylene glycol, or polypropylene glycol, or a mixture thereof.

[0352] Compositions to be used for in vivo administration can be sterile, which is readily accomplished, for example, by filtration through sterile filtration membranes.

[0353] Pharmaceutically acceptable carriers used in the parenteral products described herein include, for example, aqueous media, non-aqueous media, antibacterial agents, isotonicity agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents, or other pharmaceutically acceptable substances. Examples of aqueous media that can be incorporated into one or more of the formulations described herein include sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, dextrose or lactated Ringer's injection. Non-aqueous parenteral media that can be incorporated into one or more of the formulations described herein include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil, or peanut oil. Antimicrobial agents in bacteriostatic or fungistatic concentrations can be added to the parenteral products described herein and packaged in multi-dose containers containing phenol or cresol, mercurials, benzyl alcohol, chlorobutanol, p-hydroxybenzoic acid methyl ester and p-hydroxybenzoic acid propyl ester, thimerosal, benzalkonium chloride, or benzethonium chloride. Tonicity agents that can be incorporated into one or more of the formulations described herein include sodium chloride or dextrose. Buffers that can be incorporated into one or more of the formulations described herein include phosphate or citrate. Antioxidants that can be incorporated into one or more of the formulations described herein include sodium bisulfate. Local anesthetics that can be incorporated into one or more of the formulations described herein include procaine hydrochloride. Suspending and dispersing agents that can be incorporated into one or more of the formulations described herein include sodium carboxymethylcellulose, hydroxypropylmethylcellulose, or polyvinylpyrrolidone. An emulsifying agent that can be incorporated into one or more of the formulations described herein includes polysorbate 80 (TWEEN® 80). A sequestering or chelating agent for metal ions that can be incorporated into one or more of the formulations described herein is EDTA.Pharmaceutical carriers that can be incorporated into one or more of the formulations described herein also include ethyl alcohol, polyethylene glycol or propylene glycol for water miscible vehicles; or sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.

[0354] The exact dosage that should be adopted in pharmaceutical compositions also depends on the route of administration and the severity of the condition caused by it, and should be determined by the judgment of the doctor and the situation of each patient.For example, effective dosage can also vary depending on administration means, target site, patient's physiological condition (including age, weight and health), other medicines that are administered, or whether the treatment is preventive or therapeutic.Treatment dosage is preferably set to optimize safety and effectiveness.

[0355] 5.6 Methods of Therapeutic Use In one aspect, provided herein is a method of treating a disease in a subject by administering to a subject having the disease a fusion protein described herein, a nucleic acid encoding a fusion protein described herein, a vector comprising a nucleic acid encoding a fusion protein described herein, or a viral particle comprising a nucleic acid encoding a fusion protein described herein.

[0356] Fusion protein can be delivered to host cell by any method known in the art.For example, viral delivery system (for example, retrovirus, adenovirus, adeno-associated virus, herpesvirus, lentivirus, poxvirus, vaccinia virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, Epstein-Barr virus, influenza virus, reovirus, myxoma virus, Maraba virus, rhabdovirus, enadenotucirev or coxsackie virus) can be used to deliver the nucleic acid (for example, DNA or RNA molecule) encoding fusion protein for expression in target cell population.In some embodiments, the nucleic acid encoding fusion protein is present in episome in target cell population.In some embodiments, the nucleic acid encoding fusion protein is integrated into the genome of target cell population.In some embodiments, the virus is capable of replication.In some embodiments, the virus is replication-deficient.

[0357] In some embodiments, a fusion protein is administered to a subject. In some embodiments, a nucleic acid (DNA or RNA) is administered to a subject. In some embodiments, the nucleic acid (DNA or RNA) is complexed in a carrier (e.g., a nanoparticle, liposome, microsphere). In some embodiments, a nucleic acid (DNA or RNA) in a non-viral vector (e.g., a plasmid) encoding the fusion protein is administered to a subject.

[0358] 5.6.1 Administration Fusion protein can be delivered to host cell by any method known in the art.For example, viral delivery system (for example, retrovirus, adenovirus, adeno-associated virus, herpesvirus, lentivirus, poxvirus, vaccinia virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, Epstein-Barr virus, influenza virus, reovirus, myxoma virus, Maraba virus, rhabdovirus, enadenotucirev or coxsackie virus) can be used to deliver the nucleic acid (for example, DNA or RNA molecule) that encodes fusion protein for expression in target cell population.In some embodiments, the nucleic acid that encodes fusion protein is present in episome in target cell population.In some embodiments, the nucleic acid that encodes fusion protein is integrated into the genome of target cell population.In some embodiments, the virus can replicate.In some embodiments, the virus is replication-defective.

[0359] In some embodiments, a fusion protein is administered to a subject. In some embodiments, a nucleic acid (DNA or RNA) is administered to a subject. In some embodiments, the nucleic acid (DNA or RNA) is complexed in a carrier (e.g., a nanoparticle, liposome, microsphere). In some embodiments, a nucleic acid (DNA or RNA) in a non-viral vector (e.g., a plasmid) encoding the fusion protein is administered to a subject.

[0360] In some embodiments, the fusion protein is administered parenterally. In some embodiments, the fusion protein is administered via intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, or intrasternal injection or infusion. In some embodiments, the fusion protein is administered intravenously. In some embodiments, the fusion protein is administered subcutaneously. In some embodiments, the fusion protein is administered via a non-parenteral route or orally. Other non-parenteral routes include topical, epidermal, or mucosal administration routes, such as intranasal, intravaginal, rectal, sublingual, or topical. Administration can also be, for example, single, multiple, and / or over one or more extended periods.

[0361] In some embodiments, the methods disclosed herein are used in place of standard treatment methods. In certain embodiments, standard treatment methods are used in combination with any of the methods disclosed herein. In some embodiments, the methods disclosed herein are used after standard treatment methods have failed. In some embodiments, the fusion protein is administered simultaneously with, before, or after an additional therapeutic agent. In some embodiments, the disease is a genetic disease.

[0362] 5.6.2 Exemplary Genetic Disorders In some embodiments, the disease is a genetic disease. In some embodiments, the genetic disease is associated with decreased expression of a functional target membrane protein. In some embodiments, the genetic disease is associated with decreased stability of a functional target membrane protein. In some embodiments, the genetic disease is associated with increased ubiquitination of a target membrane protein. In some embodiments, the genetic disease is associated with increased ubiquitination and degradation of a target membrane protein. In some embodiments, the genetic disease is a haploinsufficient disease.

[0363] In some embodiments, the disease is epileptic encephalopathy. In some embodiments, the epileptic encephalopathy is early infantile epileptic encephalopathy. In some embodiments, the early infantile epileptic encephalopathy is selected from the group consisting of early infantile epileptic encephalopathy type 9, early infantile epileptic encephalopathy type 11, early infantile epileptic encephalopathy type 13, and early infantile epileptic encephalopathy type 27. In some embodiments, the disease is recurrent paroxysmal ataxia. In some embodiments, the disease is recurrent paroxysmal ataxia type 2. In some embodiments, the disease is recurrent paroxysmal kinesiogenic dyskinesia. In some embodiments, the disease is recurrent paroxysmal kinesiogenic dyskinesia type 1. In some embodiments, the disease is epilepsy. In some embodiments, the epilepsy is focal epilepsy with speech impairment and with or without mental retardation; myoclonic astatic epilepsy; epilepsy type 7; or GABRB3-related epilepsy. In some embodiments, the disease is tuberous sclerosis complex. In some embodiments, the disease is tuberous sclerosis type 1 or tuberous sclerosis type 2. In some embodiments, the disease is KCNQ2 encephalopathy.

[0364] In some embodiments, the disease is a GRIN2B-related disorder, an SCN2A-related disorder, an SCN8A-related disorder, an SLC6A1-related disorder, PRRT2 dyskinesia and epilepsy, a GRIN2A-related disorder, a CACNA1A-related disorder, an SCN9A epilepsy, PCDH19 encephalopathy, KCNQ2 encephalopathy, infantile epileptic encephalopathy type 9, early infantile epileptic encephalopathy type 11, early infantile epileptic encephalopathy type 13, early infantile epileptic encephalopathy type 27, cystic fibrosis, Dravet syndrome, Wilson's disease, recurrent paroxysmal ataxia type 2; GLUT1 deficiency syndrome, Selected from the group consisting of recurrent paroxysmal kinesigenic dyskinesia 1, epilepsy (e.g., focal with or without speech impairment and mental retardation), myoclonic-astatic epilepsy, Usher syndrome type 2A, alternating hemiplegia of childhood, alternating hemiplegia of childhood type 2, epilepsy type 7, GABRB3-associated epilepsy; tuberous sclerosis type 2; tuberous sclerosis type 1, KCNQ2-related disorder (epileptic encephalopathy), Becker muscular dystrophy, autosomal dominant RP, Alagille syndrome 1, Gillespie syndrome, and ovarian dysgenesis 1 (ODG1).

[0365] In some embodiments, the target membrane protein is GRIN2B and the disease is a GRIN2B-associated disorder (e.g., epileptic encephalopathy). In some embodiments, the target membrane protein is GRIN2B and the disease is early infantile epileptic encephalopathy. In some embodiments, the target membrane protein is GRIN2B and the disease is early infantile epileptic encephalopathy type 27. In some embodiments, the target membrane protein is CFTR and the disease is cystic fibrosis. In some embodiments, the target membrane protein is SCN1A and the disease is Dravet syndrome. In some embodiments, the target membrane protein is ATP7B and the disease is Wilson's disease. In some embodiments, the target membrane protein is CACNA1A and the disease is a CACA1A-associated disorder. In some embodiments, the target membrane protein is CACNA1A and the disease is recurrent ataxia type 2. In some embodiments, the target membrane protein is KCNQ2 and the disease is KCNQ2 encephalopathy. In some embodiments, the target membrane protein is KCNQ2 and the disease is epileptic encephalopathy. In some embodiments, the target membrane protein is SCN2A and the disease is an SCN2A-associated disorder (e.g., epileptic encephalopathy). In some embodiments, the target membrane protein is SCN2A and the disease is early infantile epileptic encephalopathy type 11. In some embodiments, the target membrane protein is SLC2A1 and the disease is GLUT1 deficiency syndrome. In some embodiments, the target membrane protein is SCN8A and the disease is an SCN8A-associated disorder (e.g., epileptic encephalopathy). In some embodiments, the target membrane protein is SCN8A and the disease is epileptic encephalopathy. In some embodiments, the target membrane protein is SCN8A and the disease is early infantile epileptic encephalopathy type 13. In some embodiments, the target membrane protein is PRRT2 and the disease is PRRPT2 dyskinesia and / or epilepsy. In some embodiments, the target membrane protein is PRRT2 and the disease is recurrent paroxysmal kinesigenic dyskinesia type. In some embodiments, the target membrane protein is PRRT2 and the disease is recurrent paroxysmal kinesigenic dyskinesia type 1. In some embodiments, the target membrane protein is GRIN2A and the disease is a GRIN2A-associated disorder.In some embodiments, the target membrane protein is GRIN2A and the disease is epilepsy. In some embodiments, the target membrane protein is GRIN2A and the disease is focal epilepsy. In some embodiments, the target membrane protein is GRIN2A and the disease is focal epilepsy with speech impairment and with or without mental retardation. In some embodiments, the target membrane protein is SLC6A1 and the disease is an SLC6A1-associated disorder. In some embodiments, the target membrane protein is SLC6A1 and the disease is epilepsy. In some embodiments, the target membrane protein is SLC6A1 and the disease is myoclonic-astatic epilepsy. In some embodiments, the target membrane protein is USH2A and the disease is Usher syndrome. In some embodiments, the target membrane protein is USH2A and the disease is Usher syndrome type 2A. In some embodiments, the target membrane protein is ATP1A2 and the disease is alternating hemiplegia of childhood. In some embodiments, the target membrane protein is ATP1A2 and the disease is alternating hemiplegia of childhood type 1. In some embodiments, the target membrane protein is ATP1A3 and the disease is alternating hemiplegia of childhood. In some embodiments, the target membrane protein is ATP1A3 and the disease is alternating hemiplegia of childhood type 2. In some embodiments, the target membrane protein is SCN9A and the disease is SCN9A epilepsy. In some embodiments, the target membrane protein is SCN9A1 and the disease is SCN9A epilepsy. In some embodiments, the target membrane protein is SCN9A1 and the disease is epilepsy. In some embodiments, the target membrane protein is SCN9A1 and the disease is epilepsy type 7. In some embodiments, the target membrane protein is PCDH19 and the disease is PCDH19 encephalopathy. In some embodiments, the target membrane protein is PCDH19 and the disease is early infantile epileptic encephalopathy. In some embodiments, the target membrane protein is PCDH19 and the disease is early infantile epileptic encephalopathy type 9. In some embodiments, the target membrane protein is GABRB3 and the disease is epilepsy. In some embodiments, the target membrane protein is GABRB3 and the disease is GABRB3-associated epilepsy. In some embodiments, the target membrane protein is TSC2 and the disease is tuberous sclerosis complex.In some embodiments, the target membrane protein is TSC2 and the disease is tuberous sclerosis type 2. In some embodiments, the target membrane protein is TSC2 and the disease is tuberous sclerosis type 1. In some embodiments, the target membrane protein is TSC1 and the disease is tuberous sclerosis. In some embodiments, the target membrane protein is TSC1 and the disease is tuberous sclerosis type 1. In some embodiments, the target membrane protein is TSC1 and the disease is tuberous sclerosis type 2. In some embodiments, the target membrane protein is KCNQ3 and the disease is KCNQ2-associated disorder (epileptic encephalopathy). In some embodiments, the target membrane protein is DMD and the disease is Becker muscular dystrophy. In some embodiments, the target membrane protein is RHO and the disease is autosomal dominant RP. In some embodiments, the target membrane protein is JAG1 and the disease is Alagille syndrome 1. In some embodiments, the target membrane protein is ITPR1 and the disease is Gillespie syndrome. In some embodiments, the target membrane protein is FSHR and the disease is ovarian dysgenesis 1 (ODG1).

[0366] 5.7 Kits In one aspect, provided herein are kits for therapeutic use comprising a fusion protein described herein, a nucleic acid encoding a fusion protein described herein, a vector comprising a nucleic acid encoding a fusion protein described herein, or a viral particle comprising a nucleic acid encoding a fusion protein described herein. The kit typically includes a label and instructions indicating the intended use of the contents of the kit. An expiration date label includes any written or recorded material provided on or with the kit, or otherwise accompanying the kit. Thus, the present disclosure provides kits for treating a subject suffering from a disease (e.g., a genetic disease), the kit including: (a) a dosage of a fusion protein, a nucleic acid encoding a fusion protein described herein, a vector comprising a nucleic acid encoding a fusion protein described herein, or a viral particle comprising a nucleic acid encoding a fusion protein described herein; and (b) instructions for using the fusion protein in any of the treatment methods disclosed herein. [Example]

[0367] This invention is further illustrated by the following examples, which should not be construed as further limiting.

[0368] 6.1 [Example 1] Generation of targeted engineered deubiquitinating enzymes This example provides a general experimental method for demonstrating enDUB-associated expression upregulation using a fluorescently tagged target protein together with a fluorophore-tagged engineered deubiquitinating enzyme (enDUB). For illustrative purposes, the constructs disclosed below are synthesized in vectors suitable for mammalian expression. Typically, the target protein is expressed with a C-terminal YFP followed by a P2A cleavage signal and an mCherry protein as a second reporter (target protein-YFP-P2A-mCherry). This construct is co-transfected in the presence of a trifunctional fusion protein (CFP-P2A-anti-YFP nanobody-enDUB) consisting of a CFP protein followed by a P2A signal and an engineered DUB followed by a nanobody that specifically binds to YFP. In therapeutic applications, a targeting nanobody (or other specific binder) is directed against the wild-type (or disease-causing mutant) protein to be upregulated in cells, while the enDUB is fused to a binding protein for the target protein. The target protein binding moiety can be any antibody or antibody fragment, nanobody, or any other non-antibody scaffold, such as fibronectin, anticalin, ankyrin repeat, or natural binding protein, that specifically interacts with the target protein to be upregulated. The amino acid sequences of the components of the tested fusion proteins are provided in Table 4 below.

[0369] [Table 4-1]

[0370] [Table 4-2]

[0371] [Table 4-3]

[0372] The amino acid sequences of the fusion proteins tested are provided in Table 5 below.

[0373] [Table 5-1]

[0374] [Table 5-2]

[0375] [Table 5-3]

[0376] [Table 5-4]

[0377] [Table 5-5]

[0378] [Table 5-6]

[0379] [Table 5-7]

[0380] [Table 5-8]

[0381] [Table 5-9]

[0382] [Table 5-10]

[0383] 6.2 [Example 2] Testing targeted engineered deubiquitinases To demonstrate upregulation of a target protein in the context of specific targeting enDUBs, the following experiment is performed. Overview of the structures used: Control experiments using non-targeting enDUB fusions 〇 Target-YFP-P2A-mCherry CFP-P2A-enDUB (non-targeting control enDUB) Test constructs for upregulation: 〇 Target-YFP-P2A-mCherry CFP-P2A-α-YFP nanobody-enDUB or a specific targeting enDUB fusion consisting of: CFP-P2A-anti-targeting binder-enDUB

[0384] A plasmid carrying a YFP-tagged target protein is co-transfected into HEK cells with a plasmid carrying an enDUB fused to a target-binding protein. A control construct carrying an enDUB without a targeting binder is also co-transfected with the labeled target protein. 24-48 hours later, transfected cells are analyzed by FACS or by upregulation from the control. The mCherry signal on the target protein is used to normalize for transfection efficiency, while the CFP signal is used to normalize for transfection efficiency of the enDUB construct. The YFP fused to the target protein is a readout for target gene expression, which is plotted against the signal in the control transfection. A relative increase in YFP fluorescence from the control demonstrates upregulation in the presence of enDUB.

[0385] 6.3 [Example 3] Screening Assays for Testing Fusion Proteins The following example describes an assay for analyzing the ability of a targeted engineered deubiquitinase (enDub) (e.g., the enDub described herein) to increase expression of a target protein. Generally, the assay involves tagging the target protein with a fluorescent tag (e.g., NanoLuciferase (NLuc)) and an alpha-tag (α-tag); and tagging a fusion protein of enDub and an anti-alpha tag nanobody with a different fluorescent tag (e.g., firefly luciferase (FLuc)) via a cleavable linker. The use of two different fluorescent tags allows for signal normalization to compensate for variations in transfection / expression, as the second fluorescent tag is rapidly cleaved from the enDub-anti-alpha tag fusion protein intracellularly upon cleavage of the cleavable linker. Figure 2 provides a general schematic of the cellular aspect of the assay. The protocol, including materials and methods, is described below.

[0386] CHO-K1 cells were digested with 0.25% (w / v) trypsin-EDTA at 37°C for 5 minutes. The digestion was stopped by adding complete medium to the CHO-K1 cell culture. The CHO-K1 cells were centrifuged at 800 rpm for 5 minutes. After centrifugation, the supernatant was discarded, and the CHO-K1 cells were resuspended in 2 mL of medium and counted. 6CHO-K1 cells were electroporated at 440V with 0.5 μg of plasmid encoding NLuc- and alpha-tag-tagged target proteins and 1 μg of plasmid encoding a) enDub-anti-alpha tag nanobody-FLuc fusion protein (experimental), b) enDub (control), or anti-alpha tag nanobody (control). 5E+4 cells per well were plated in a 24-well plate and cultured at 37°C and 5% CO for 24 hours. Cells were digested with 0.25% (w / v) trypsin-EDTA at 37°C for 5 minutes. Complete medium was added to the culture to stop the digestion, and cells were counted for use in the NanoGlo® Dual Luciferase® Assay (Promega). This assay allows for the detection of FLuc and NLuc® in a single sample. The NanoGlo® Dual-Luciferase® Assay was performed according to the manufacturer's instructions (Promega, Nano-Glo® Dual-Luciferase® Reporter Assay Technical Manual #TM426). Briefly, 1E+4 cells / well were plated into a 96-well black plate and cultured at 37°C, 5% CO2 for 24 hours. The plate was removed from the incubator and allowed to equilibrate to room temperature. Samples were modified as necessary to have a starting volume of 80 μl / well. 80 μl of ONE-Glo™ EX Reagent was injected into all sample wells and incubated for 3 minutes. Firefly luminescence was read in all sample wells using a 1-second integration time. 80 μl of NanoDLR™ Stop & Glo® Reagent was injected into all sample wells; incubated for 5 minutes. NanoLuc® luminescence was read in all sample wells using a 1-second integration time. The dispense lines were washed and the data analyzed per the manufacturer's instructions (Nano-Glo® Dual-Luciferase® Reporter Assay Technical Manual #TM426.).

[0387] The amino acid sequences of the components of the fusion proteins used in the assay are detailed in Table 6 below.

[0388] [Table 6]

[0389] The amino acid sequences of exemplary target fusion proteins comprising a target protein, NLuc, and an alpha tag are detailed in Table 7 below.

[0390] [Table 7-1]

[0391] [Table 7-2]

[0392] [Table 7-3]

[0393] [Table 7-4]

[0394] [Table 7-5]

[0395] [Table 7-6]

[0396] [Table 7-7]

[0397] [Table 7-8]

[0398] The amino acid sequences of exemplary fusion proteins containing control or targeted engineered deubiquitinating enzymes are detailed in Table 8 below.

[0399] [Table 8-1]

[0400] [Table 8-2]

[0401] Assays were performed utilizing the tagged proteins and targeted enDub described in Tables 7 and 8 above. Results from KCNQ1 targeting, showing a 3.8-fold increase in KCNQ1 protein expression, are shown in Figure 3. Results from SCN1A targeting, showing a 4.4-fold increase in SCN1A protein expression, are shown in Figure 4. Results from GRIN2B targeting, showing a 5.3-fold increase in GRIN2B protein expression, are shown in Figure 5. Results from SLC50A1 targeting, showing a 2.03-fold increase in SLC50A1 protein expression, are shown in Figure 6. Results from TREM258 targeting, showing a 2.77-fold increase in TREM258 protein expression, are shown in Figure 7. Results from FSHR targeting, showing a 1.33-fold increase in FSHR protein expression, are shown in Figure 8. The control used for the SLC50A1, TREM258, and FSHR experiments was an engineered deubiquitinase without a nanobody targeting the alpha-tag. Transduction efficiency was normalized using the firefly luciferase signal as a reference and the ratio of the NLuc signal divided by the firefly luciferase signal plotted on the y-axis.

[0402] The present invention should not be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

[0403] All references (e.g., publications or patents or patent applications) cited herein are incorporated by reference in their entirety for all purposes to the same extent as if each individual reference (e.g., publication or patent or patent application) was specifically and individually indicated to be incorporated by reference in its entirety for all purposes. Other embodiments are within the scope of the following claims.

Claims

1. a. an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or variant thereof, b. A targeting domain that includes a targeting moiety that specifically binds to a membrane protein that is not an ion channel. An effector domain operably linked to: A nucleic acid molecule encoding a fusion protein comprising:

2. 2. The nucleic acid molecule of claim 1, wherein the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 80, 1-79, 81-112, or 447.

3. 2. The nucleic acid molecule of claim 1, wherein the catalytic domain comprises a catalytic domain derived from a deubiquitinase that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 80, 1-79, 81-112, or 447.

4. 2. The nucleic acid molecule of claim 1, wherein the catalytic domain comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 293 or 113-220.

5. The nucleic acid molecule of claim 1 , wherein the portion that specifically binds to a membrane protein comprises an antibody, or a functional fragment or functional variant thereof.

6. The nucleic acid molecule of claim 5 , wherein the antibody, or functional fragment or functional variant thereof, comprises a VHH.

7. 2. The nucleic acid molecule of claim 1, wherein the membrane protein is selected from the group consisting of solute carrier family 2, facilitative glucose transporter member 1 (SLC2A1), proline-rich transmembrane protein 2 (PRRT2), usherin (USH2A), protocadherin-19 (PCDH19), tuberin (TSC2), hamartin (TSC1), dystrophin (DMD), rhodopsin (RHO), Jagged 1 protein (JAG1), inositol 1,4,5-triphosphate receptor type 1 (ITPR1), sugar transporter SWEET1 (SLC50A1), transmembrane protein 258 (TMEM258), or follicle stimulating hormone receptor (FSHR).

8. 2. The nucleic acid molecule of claim 1, wherein the membrane protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs:221-227 or 243-245.

9. The nucleic acid molecule of claim 1 , wherein the effector domain is indirectly operably linked to the targeting domain via a peptide linker.

10. a. an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or variant thereof; b. Ionotropic glutamate receptor NMDA 2B (GRIN2B), cystic fibrosis transmembrane conductance regulator (CFTR), sodium channel protein type 1 subunit alpha (SCN1A), copper transporting ATPase 2 (ATP7B), potassium voltage-dependent channel subfamily KQT member 2 (KCNQ2), sodium channel protein type 2 subunit alpha (SCN2A), voltage-dependent P / Q-type calcium channel subunit alpha-1A (CACNA1A), sodium channel protein type 8 subunit alpha (SCN8A), ionotropic glutamate receptor NMDA a targeting domain comprising a targeting moiety that specifically binds to a membrane protein selected from the group consisting of GRIN2A, sodium and chloride-dependent GABA transporter 1 (SLC6A1), sodium / potassium transporting ATPase subunit alpha-2 (ATP1A2), sodium / potassium transporting ATPase subunit alpha-3 (ATP1A3), sodium channel protein type 9 subunit alpha (SCN9A), gamma-aminobutyric acid receptor subunit beta-3 (GABRB3), and potassium voltage-gated channel subfamily KQT member 3 (KCNQ3); A fusion protein comprising:

11. The nucleic acid molecule of claim 1 which is a DNA molecule or an RNA molecule.

12. A vector comprising the nucleic acid molecule described in claim 1.

13. The vector described in claim 12, which is a viral vector.

14. A viral particle comprising the nucleic acid molecule described in claim 1.

15. A pharmaceutical composition comprising the nucleic acid molecule of claim 1 and an excipient.

16. A pharmaceutical composition for treating a genetic disease, comprising the nucleic acid molecule described in claim 1.

17. The pharmaceutical composition of claim 16, wherein the genetic disease is a haploinsufficiency disease.

18. 17. The pharmaceutical composition of claim 16, wherein the disease is PCDH19 encephalopathy, early infantile epileptic encephalopathy type 9, tuberous sclerosis type 2; tuberous sclerosis type 1, Becker muscular dystrophy, autosomal dominant RP, Alagille syndrome 1, Gillespie syndrome, or ovarian dysgenesis 1 (ODG1).

19. kk. the target membrane protein is PCDH19 and the disease is PCDH19 encephalopathy; ll. the target membrane protein is PCDH19 and the disease is early infantile epileptic encephalopathy; mm. the target membrane protein is PCDH19 and the disease is early infantile epileptic encephalopathy type 9; pp. the target membrane protein is TSC2 and the disease is tuberous sclerosis; qq. the target membrane protein is TSC2 and the disease is tuberous sclerosis type 2; rr. the target membrane protein is TSC2 and the disease is tuberous sclerosis type 1; ss. the target membrane protein is TSC1 and the disease is tuberous sclerosis; tt. the target membrane protein is TSC1 and the disease is tuberous sclerosis type 1; uu. The target membrane protein is TSC1 and the disease is tuberous sclerosis type 2; The target membrane protein is DMD and the disease is Becker muscular dystrophy; xx. the target membrane protein is RHO and the disease is autosomal dominant RP; yy. the target membrane protein is JAG1 and the disease is Alagille syndrome 1; zz. the target membrane protein is ITPR1 and the disease is Gillespie syndrome; or The pharmaceutical composition of claim 16, wherein the target membrane protein is FSHR and the disease is ovarian dysgenesis 1 (ODG1).